A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD Taken Daily at Bedtime (Protocol No. TNX-CY-P302)
Phase: PHASE3
Conditions: PTSD
Sponsor: Tonix Pharmaceuticals, Inc.

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
TNX-102 SL (CYCLOBENZAPRINE HCL SUBLINGUAL TABLETS) 
TNX-CY-P302 
A PHASE 3, DOUBLE-BLIND, RANDOMIZED, 
MULTICENTER, PLACEBO-CONTROLLED STUDY TO 
EVALUATE THE EFFICACY AND SAFETY OF TNX-102 SL 
IN PARTICIPANTS WITH PTSD TAKEN DAILY AT 
BEDTIME  
 
“RECOVERY” STUDY 
 
 
 
Original Protocol Release Date:  21 November 2018 
Amendment 01: 02 January 2019 
Amendment 02: 19 March 2019 
Amendment 03: 23 December 2019 
US IND No. 115936 
 
 
Sponsor: 
Tonix Pharmaceuticals, Inc. (Tonix) 
 
 
 
 
Confidentiality Statement: The information herein contains trade secrets and commercial information that are 
privileged or confidential and the proprietary property of Tonix Pharmaceuticals.  Any unauthorized use or 
disclosure of such information without the prior written authorization of Tonix is expressly prohibited. No part of 
this document may be reproduced or transmitted in any form without written permission from Tonix, except as 
required by federal or state laws.  Persons to whom this information is disclosed by written consent must be informed 
that all the information herein is privileged and confidential and may not be further divulged.  These restrictions on 
disclosure will apply equally to all future information supplied to you that is indicated to be privileged or confidential. 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 2 of 84 
 
INVESTIGATOR’S AGREEMENT 
I have read the TNX-CY-P302 protocol and agree to conduct the study as outlined.  I agree to 
maintain the confidentiality of all information received or developed in connection with this 
protocol.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Printed Name of Investigator 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Signature of Investigator 
 
 
 
 
 
 
 
 
Date 
 
 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 3 of 84 
 
2. 
SYNOPSIS 
Name of Sponsor/Company: 
Tonix Pharmaceuticals, Inc. 
Name of Investigational Product: 
TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) 
Name of Active Ingredient: 
Cyclobenzaprine HCl 
Title of Study: 
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the 
Efficacy and Safety of TNX-102 SL in Participants with PTSD Taken Daily at Bedtime (Protocol No. 
TNX-CY-P302)  
Study center(s): Approximately 25-30 centers in the United States 
Objectives: 
Primary: 
To evaluate the efficacy of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) in the treatment of 
posttraumatic stress disorder (PTSD) 
Secondary: 
To evaluate the safety of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) in the treatment of 
PTSD 
Methodology:  
This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose study that 
will investigate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) – a sublingual 
formulation of cyclobenzaprine.  Following successful screening and randomization, eligible patients 
will have a telephonic visit at Week 2 and then return to the study clinic for monthly visits at Week 4, 
Week 8, and Week 12 for assessments of efficacy and safety. 
There will be a total of 6 study visits over approximately 13-15 weeks of study participation, 
including Screening (Visit 1), Randomization (Day 1, Visit 2), a phone visit after 2 weeks of 
treatment and in-clinic visits after 4, 8, and 12 weeks of treatment.  A total of approximately 250 
patients will be randomized in a 1:1 ratio to placebo or TNX-102 SL 5.6 mg (2 x 2.8 mg tablets). 
Number of patients (planned):  
Approximately 250 patients will be randomized.  Randomized patients who withdraw will not be 
replaced. 
Diagnosis and main criteria for inclusion:  
Inclusion criteria (assessed at Screening Visit 1): 
1. Male or female between 18 and 75 years of age, inclusive. 
2. Diagnosed with current PTSD as determined by the Clinician-Administered PTSD Scale 
(CAPS-5) for Diagnostic and Statistical Manual of Mental Disorders-Version 5 (DSM-5) and 
of sufficient symptom severity, defined as all of the following at Screening Visit 1 using the 
Diagnostic version (1-month recall): 
a. The A criterion is 1=YES, and 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 4 of 84 
 
b. At least ONE item of the B criterion items must have a score of ≥2, and 
c. At least ONE item of the C criterion items must have a score of ≥2, and 
d. At least TWO items of the D criterion items must have a score of ≥2, and 
e. At least TWO items of the E criterion items must have a score of ≥2, and  
f. The F item 22 criterion is 1=YES (≥1-month duration of symptoms) 
g. At least ONE item of the G items must have a score of ≥2, and 
h. The total CAPS-5 score (of items 1 through 20 is) ≥29 
3. Index trauma(s) resulting in PTSD must meet the following: 
a. DSM-5 criterion A for PTSD as described in the CAPS-5 and Criterion A – Assessment 
Form (CA-AF), and 
b. Must have occurred within 9 years of Screening Visit 1, and 
c. Must have occurred ≥ 3 months prior to the Screening Visit, and 
d. Must have occurred when the patient was ≥18 years of age.  
4. Willing and able to withdraw and refrain from opioids for the course of the study. 
5. Willing to refrain from use of all other formulations of cyclobenzaprine for the course of the 
study. 
6. Willing and able to refrain from antidepressants, antipsychotics, mood stabilizers, 
anticonvulsants, benzodiazepines, non-benzodiazepine hypnotics, buspirone, stimulants (e.g. 
amphetamines, methylphenidate, modafinil, armodafinil), prazosin and trazodone for the 
course of the study. 
7. Capable of reading and understanding English and able to provide written informed consent 
to participate. Separate written, signed informed consent will be required if the patient is to 
participate in the optional pharmacogenomic assessment. A decision not to participate in 
optional pharmacogenomic testing will not affect the subject’s eligibility for the main study. 
8. If female, either not of childbearing potential (defined as postmenopausal for at least one year 
or surgically sterile [e.g., bilateral tubal ligation; bilateral oophorectomy; hysterectomy, etc.]) 
or practicing one of the following medically acceptable methods of birth control throughout 
the study: 
a. Hormonal methods such as oral, implantable, injectable, or transdermal contraceptives for 
a minimum of one full cycle (based on the patient’s usual menstrual cycle period) before 
study drug administration; 
b. Intrauterine device (IUD); 
c. Double-barrier method (condoms, sponge, diaphragm, or vaginal ring with spermicidal 
jellies or cream); 
d. In sexually-exclusive relationship with vasectomized male partner, or in same-sex 
relationship with no plans for artificial or other forms of insemination. 
9. Willing and able to comply with all protocol-specified requirements. 
10. If patient has received trauma-focused treatment (e.g., cognitive behavioral therapy for 
PTSD, prolonged exposure therapy, desensitization therapy, etc.), it must have been 
completed at least three months prior to the Baseline visit, and there can be no plans to 
initiate this type of therapy during study.  General psychotherapy that was in process at time 
of Screening may be continued during the trial, but no new initiation of any type of 
psychotherapy treatment is allowed during the trial after enrollment. 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 5 of 84 
 
Exclusion Criteria 
1. Current or ongoing exposure to the trauma that resulted in the PTSD. 
2. Increased risk of suicide on the basis of the Investigator’s judgment and/or the results of the 
Mini International Neuropsychiatric Interview, Version 7.0.2 (MINI 7.0.2) conducted at 
Screening and the Columbia Suicide Severity Rating Scale (C-SSRS) conducted at Screening 
and/or Baseline and Item 10 of the Montgomery-Åsberg Depression Rating Scale (MADRS) 
at Screening and/or Baseline.  Any of the following will be exclusionary: 
a. High suicidality based on a MINI Module B score ≥ 17 (Screening); or, 
b. Patient answers YES to either MINI question B10 or B11 (Screening); or, 
c. Patient meets criteria for CURRENT Suicidal Behavior Disorder on the MINI 
(Screening); or, 
d. C-SSRS Type 4 or Type 5 ideation within 6 months of Screening or at the Baseline visit; 
or, 
e. Any suicidal behavior in the past 12 months as identified by the C-SSRS at Screening or 
Baseline. 
f. A score of > 4 on Item 10 of the MADRS at Screening or Baseline. 
3. Increased risk of suicide, based on the Investigator’s judgment that is of a severity that is not 
appropriate for outpatient management, or that warrants additional therapy excluded by the 
protocol. 
4. Significant (e.g., moderate or severe) comorbid traumatic brain injury (TBI) by history.  
Based on past history and Investigator’s judgment, patients with mild TBI are eligible. 
5. Severe depression suggested by a Screening (Visit 1) MADRS score > 26.   Patients with a 
Screening MADRS score of > 26 may be randomized upon Medical Monitor approval, based 
on a review of all Screening rating scales and the patient’s psychiatric/medical history.         
6. Clinically significant laboratory abnormalities based on screening laboratory tests and/or 
medical history in the Investigator’s opinion, including a Thyroid Stimulating Hormone 
(TSH) level > 1.5 times the upper limit of normal and aspartate aminotransferase (AST) 
and/or alanine aminotransferase (ALT) > 3 times the upper limit of normal (if persistent upon 
repeat).  Patients with treated thyroid conditions and TSH levels < 1.5 times the upper limit of 
normal will be eligible to participate in the study. 
7. Diagnosed with clinically significant and currently relevant cardiac disease (e.g., significant 
arrhythmia; heart block; heart failure) or recent myocardial infarction [within the past 2 
years]) or QTcF > 450 msec (male) or > 470 msec (female) on the screening 
electrocardiogram (ECG). 
8. Current evidence of human immunodeficiency virus (HIV) infection based on screening 
laboratory results or medical history, or clinically significant hepatitis B or C infection as 
defined by current treatment or liver function tests (e.g., aspartate aminotransferase [AST] or 
alanine aminotransferase [ALT] > 3 times the upper limits of normal). 
9. Use of antidepressant medication within 2 months of Baseline, with the exception of 
trazodone at doses ≤ 150 mg per day or tricyclic antidepressants at doses ≤ 50 mg per day for 
the purpose of treating insomnia, which instead require a 1-week drug-free interval prior to 
the Baseline visit. 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 6 of 84 
 
10. Unable to successfully wash out of the following medications during screening, or in whom 
washout is medically inadvisable: anticonvulsants, mood stabilizers, antipsychotic agents, 
opioids, benzodiazepines, non-benzodiazepine hypnotics (zolpidem, eszopiclone, zaleplon), 
buspirone, trazodone, stimulants (e.g., amphetamine mixed salts, methylphenidate, 
lisdexamphetamine, dextroamphetamine, modafanil, armodafanil), atomoxetine,  or any 
medication known to be a potent (strong) cytochrome P450 subtype 3A4 (CYP3A4) inhibitor, 
or St. John’s wort.  Note:  Use of caffeine and/or nicotine is permitted. 
11. Unable to successfully wash out of alpha-adrenergic antagonists and/or agonists (e.g., 
prazosin, terazosin, doxazosin, tamsulosin, silodosin, tizanidine, clonidine, guanfacine) or 
when washout is medically inadvisable. 
12. Positive results for illegal or abused substances other than cannabis at Screening or Baseline 
or history of substance use disorder during the preceding 6 months as defined by the 
screening MINI 7.0.2.  Patients who utilize alcohol and/or cannabis but do not meet criteria 
for greater than MILD alcohol and/or cannabis use disorder are suitable for the study 
provided that, in the judgment of the Investigator, this usage will not interfere with the 
patient’s ability to complete the study or provide reliable data. 
13. Any clinically significant, uncontrolled, or unstable medical or surgical condition that could 
affect a patient’s ability to participate in the study or potentially compromise a patient’s well-
being during the study, including patients with a history of untreated or uncontrolled angle-
closure glaucoma.   
14. Diagnosis of DSM-5-defined bipolar disorder I, II or unspecified, schizophrenia, 
schizoaffective disorder, obsessive-compulsive disorder, major depressive disorder (MDD) 
with psychotic features, other psychotic disorder, or antisocial personality disorder as 
confirmed by the MINI Version 7.0.2. 
15. History of or evidence for a diagnosis of borderline personality disorder (BPD) based on a 
score of ≥ 7 on the McLean Screening Instrument (MLI) for BPD at Visit 1 (Screening) and 
Investigator determination that the rated symptoms of BPD are not simply due to overlap with 
PTSD symptomatology.  Patients who score ≥ 7 on the MLI may be randomized upon 
Medical Monitor approval if the high score does appear to be a result of overlap of PTSD 
symptoms rather than presence of BPD. 
16. Anticipated need for surgery that might confound results or interfere with patient’s ability to 
comply with the protocol. 
17. Female patients who are pregnant or lactating. 
18. History of serotonin syndrome, severe allergic reaction or bronchospasm or known 
hypersensitivity to cyclobenzaprine or the excipients in TNX-102 SL or placebo 
formulations. 
19. Seizure disorder other than history of childhood febrile seizures. 
20. Current sleep apnea not well controlled by Continuous Positive Airway Pressure (CPAP) or 
oral (mouthpiece) devices.  Patients with mild obstructive sleep apnea or those well 
controlled by CPAP or oral (mouthpiece) devices are allowed at the discretion of the 
Investigator. 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 7 of 84 
 
21. Patients with a body mass index (BMI) > 40. 
22. Has received any other investigational drug within 90 days before Screening or has taken 
cyclobenzaprine within 21 days of the Randomization visit. 
23. Previous participation in any other study with TNX-102 SL. 
24. Any existing oral medical or dental condition that could potentially interfere with sublingual 
administration of study drug, or history of severe or unexplained oral or oropharyngeal 
swelling or edema. 
25. Family member of investigative staff. 
26. In the process of litigating for compensation for a psychiatric disorder. 
Randomization Criteria:  All of the following must be met before the patient is eligible for 
randomization at Visit 2: 
1. Patient continues to meet all inclusion and exclusion criteria, including urine and blood test 
results, and 
2. Visit 2 total CAPS-5 score ≥ 33 (“Symptom Severity” version using 1-week recall), and 
3. No active suicidal intent or plan, or suicidal behavior, based on Investigator’s judgment and 
Visit 2 C-SSRS responses (e.g., no C-SSRS Type 4-5 ideation or suicidal behavior since Visit 
1) and/or a score of > 4 on Item 10 of the Visit 2 MADRS. 
Investigational product, dosage and mode of administration: 
Name: TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 
Dose, route, frequency: 2 tablets of TNX-102 SL 2.8 mg taken simultaneously and sublingually 
(under the tongue) each day at bedtime starting on Day 1 for 12 weeks. 
Duration of treatment: 
12 weeks 
Reference therapy, dosage and mode of administration: 
Name: Placebo 
Dose, route, frequency: 2 placebo tablets taken simultaneously and sublingually (under the tongue) 
each day at bedtime starting on Day 1 for 12 weeks. 
Criteria for evaluation: 
Primary Efficacy Endpoint: 
• 
The mean change from baseline (Visit 2) in the Total CAPS-5 score evaluated at Week 
12. 
Secondary Efficacy Endpoints: The efficacy endpoints listed below are considered key secondary 
endpoints and will be tested in the following order: 
• 
Change from baseline to Week 12 in CGI-S score. 
• 
Change from baseline to Week 12 in the SDS total score. 
• 
Change from Baseline to Week 12 in the PROMIS Sleep Disturbance total score. 
A fixed sequence procedure will be applied to the above key secondary efficacy endpoints to 
adjust for multiplicity and to control for overall type I error. 
 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 8 of 84 
 
Other Secondary Efficacy Endpoints: 
• 
Change from baseline to Week 12 in the disruption of work/school activities assessed 
using the SDS. 
• 
Change from baseline to Week 12 in disruption of social life/ leisure activities assessed 
using the SDS. 
• 
Change from Baseline to Week 12 in the disruption of family life/home responsibilities 
assessed using the SDS. 
• 
Change from baseline to Week 12 in CAPS-5 Arousal and Reactivity (Criterion E) score. 
• 
Change from baseline to Week 12 in CAPS-5 Intrusion symptoms (Criterion B) score. 
• 
Change from baseline to Week 12 in CAPS-5 Negative Cognition and Mood (Criterion 
D) score. 
• 
Change from baseline to Week 12 in CAPS-5 Persistent Avoidance (Criterion C) score. 
• 
Change from baseline to Week 12 in CAPS-5 Sleep Disturbance (item E6) score. 
• 
Change from baseline to Week 12 in CGI-I 
• 
Change from baseline to Week 12 in mean PGIC score. 
• 
Proportion of patients with a treatment response on the CGI-I defined as a CGI-I score of 
“much improved” or “very much improved” at Week 12. 
• 
Proportion of patients with a PGIC score of “much improved” or “very much improved” 
at Week 12. 
• 
Proportion of patients with a Total CAPS-5 score of 0–10 (asymptomatic/few symptoms) 
at Week 12. 
• 
Proportion of patients with a Total CAPS-5 score of 0-22 (asymptomatic or mild 
PTSD/subthreshold) at Week 12. 
• 
Proportion of patients with Response, defined as a ≥ 10-point improvement from baseline 
to Week 12 in Total CAPS-5 score. 
• 
Proportion of patients with Loss of Diagnosis, defined as Response AND no longer 
meeting DSM-5 symptom criteria in any one or more of the four clusters (B, C, D, E) at 
Week 12. 
• 
Proportion of patients in Remission, defined as Loss of Diagnosis AND Total CAPS-5 
score ≤ 10 at Week 12. 
• 
Proportion of patients achieving sustained Remission, defined as Loss of Diagnosis AND 
a Total CAPS-5 score ≤ 10 after both 8 weeks AND 12 weeks of treatment. 
• 
Proportion of patients with a ≥30% reduction from baseline to Week 12 in Total CAPS-5 
score 
• 
Proportion of patients with a ≥50% reduction from baseline to Week 12 in Total CAPS-5 
score. 
• 
Change from baseline to Week 12 in MADRS score. 
• 
Change from baseline to Week 12 in CAPS-5 Reckless or Self-Destructive Behavior 
(item E2) score. 
• 
Changes from baseline in patient-rated Changes in Sexual Functioning Questionnaire 
Short-Form (CSFQ-14) in males and in females, analyzed separately 
Exploratory Endpoints:  Any exploratory endpoints will be delineated in the statistical analysis plan 
(SAP). 
Safety 
Safety will be assessed by: 
• 
Adverse events (AE) and serious AEs (SAEs) throughout the entire duration of the study, 
including detailed assessment of AEs involving the oral cavity 
• 
Changes from baseline in clinical laboratory test results 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 9 of 84 
 
• 
Changes from baseline in vital signs and weight 
• 
Change from baseline in MADRS score 
• 
Changes from baseline indicative of increased suicidal ideation or behavior as assessed 
by the Columbia Suicide Severity Rating Scale (C-SSRS) 
• 
Changes from baseline in patient-rated Changes in Sexual Functioning Questionnaire 
Short-Form (CSFQ-14) in males and in females, described separately 
Statistical methods: 
Analysis Populations 
• 
Safety Population (SAFETY): All patients who receive at least one dose of 
investigational product, analyzed as treated. 
• 
Modified Intent-to-Treat Population (mITT):  All randomized patients who have at least a 
baseline and one post-baseline CAPS-5 assessment, analyzed as randomized. 
 
Efficacy Analyses 
The primary efficacy analysis will use a mixed model repeated measures (MMRM) approach to 
estimate the mean change from baseline in the Total CAPS-5 score evaluated at Week 12 in the TNX-
102 SL 5.6 mg and placebo arms.  The model will include all patients in the mITT population, and 
missing values will be imputed using a multiple imputation (MI) approach.  The dependent variable 
will be the observed change from baseline in total CAPS-5 score at each post-randomization in-clinic 
visit.  Covariates in the model will include the fixed categorical effects of treatment, site, sex, and 
treatment by visit interaction, as well as the continuous fixed covariates of baseline score and baseline 
score by visit interaction.  
 
MMRM methodology will be utilized for the secondary endpoints as appropriate.  Binary data, e.g., 
CGI-I response, will be analyzed using a Cochran-Mantel-Haenszel (CMH) test controlling for the 
randomization stratification variable of sex.  Patients with missing data will be analyzed as though 
they are non-responders for binary endpoints. A fixed sequence procedure will be applied to the key 
secondary efficacy endpoints to adjust for multiplicity and to control for overall type I error. 
 
Safety Analyses 
Adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) 
version in use at the start of the study and will be summarized overall and by preferred term and 
system organ class.  Adverse events will also be summarized by severity and relationship to study 
drug.  Serious AEs and AEs leading to discontinuation of study drug will also be summarized.  Actual 
values and changes from baseline for clinical laboratory test results, vital sign measurements, 
MADRS scores, and CSFQ-14 scores will be summarized at endpoint using descriptive statistics (n, 
mean, SD, median, minimum, and maximum). 
 
The number of patients with screening, baseline and treatment-emergent suicidal ideation and/or 
behavior, based on the C-SSRS will be summarized by treatment group. 
 
Interim Analysis 
An interim analysis will be performed once approximately 50% of the planned patients have enrolled 
and those patients have either completed or discontinued the study.  The purpose of the interim will 
be to potentially increase the sample size to maintain statistical power conditioned on the results of 
the first 50% of patients; or stop the study for futility if the conditional power is sufficiently low.  The 
study team will only be informed of the recommendation to maintain the original sample size, 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 10 of 84 
 
increase the sample size (by a fixed, pre-specified amount) or discontinue the study (at which point 
unblinding would occur).    
For the primary and key secondary outcomes, the results from before and after the interim will be 
combined with Cui, Hung, Wang (CHW) methodology (Cui, 1999).  Full details of the interim 
analysis procedure and steps to maintain treatment blinding of the study team will be described in the 
SAP and the IDMC Charter and finalized prior to execution of the interim analysis. 
Sample Size Estimation 
The study is planned to enroll approximately 250 patients total in a 1:1 randomization, that is, 125 
patients in each of the TNX-102 SL 5.6 mg and placebo arms.  
 
 
    
 
Pharmacogenomic Analyses 
Potential genetic determinants of treatment response will be examined by the assessment of genetic 
variants in relation to treatment outcome. A blood sample will be obtained from patients who have 
signed a separate informed consent form for the pharmacogenomic analyses.  The blood sample can 
be obtained at any visit post Screening, and the patient has agreed to be tested and has signed the 
separate informed consent form; i.e., the blood draw is not tied to any specific study visit, hence it can 
be obtained at any time post Screening.   
 
The first step of the pharmacogenomic analyses will involve exome sequencing and analysis for 
allelic polymorphisms related to treatment response to TNX-102 SL. It is presumed that unused 
sample will be stored up to fifteen years, and potentially utilized to develop a pharmacogenomic test 
for determining likelihood of treatment response to TNX-102 SL.   
 
 
 
 
 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 11 of 84 
 
3. 
TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF 
FIGURES 
TABLE OF CONTENTS 
1. 
TITLE PAGE ................................................................................................................1 
2. 
SYNOPSIS ...................................................................................................................3 
3. 
TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF FIGURES ...............11 
4. 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS.............................17 
5. 
INTRODUCTION ......................................................................................................21 
5.1. 
Sleep and PTSD ..........................................................................................................22 
5.1.1. 
Brief Summary of Prior Clinical Experience, Dose Rationale and 
Justification of Study Design ......................................................................................23 
6. 
TRIAL OBJECTIVES AND PURPOSE ....................................................................26 
6.1. 
Primary Objective .......................................................................................................26 
6.2. 
Secondary Objectives .................................................................................................26 
7. 
INVESTIGATIONAL PLAN .....................................................................................26 
7.1. 
Overall Study Design ..................................................................................................26 
7.2. 
Number of Patients and Treatment Assignment .........................................................27 
7.3. 
Study Endpoints ..........................................................................................................27 
7.3.1. 
Primary efficacy endpoint ...........................................................................................27 
7.3.2. 
Secondary efficacy endpoints .....................................................................................28 
7.3.2.1. 
Key Secondary Efficacy Endpoints ............................................................................28 
7.3.2.2. 
Other Secondary Efficacy Endpoints ..........................................................................28 
7.3.3. 
Exploratory efficacy endpoints ...................................................................................29 
7.3.4. 
Safety ..........................................................................................................................29 
7.4. 
Efforts to Minimize Missing Data ..............................................................................30 
8. 
SELECTION AND WITHDRAWAL OF PATIENTS ..............................................30 
8.1. 
Informed Consent .......................................................................................................30 
8.2. 
Inclusion Criteria ........................................................................................................30 
8.3. 
Exclusion Criteria .......................................................................................................32 
8.4. 
Randomization Criteria ...............................................................................................34 
8.5. 
Prior and Concomitant Medications ...........................................................................34 
8.5.1. 
Allowed Concomitant Medications ............................................................................36 
8.6. 
Withdrawal Criteria ....................................................................................................36 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 12 of 84 
 
9. 
STUDY DRUG MATERIALS AND MANAGEMENT ...........................................36 
9.1. 
Study Drug Packaging, and Labeling and Storage .....................................................36 
9.2. 
Dosing Instructions .....................................................................................................37 
9.3. 
Dispensing Instructions ..............................................................................................37 
9.4. 
Release of Clinical Study Supplies to the Investigator ...............................................38 
9.5. 
Study Drug Accountability and Reconciliation ..........................................................38 
10. 
STUDY VISITS AND PROCEDURES .....................................................................39 
10.1. 
Visit 1 (Screening: Day -21 to -7) ..............................................................................39 
10.1.1. 
Informed Consent .......................................................................................................39 
10.1.2. 
Screening Overview ....................................................................................................39 
10.1.3. 
Patient Numbering ......................................................................................................39 
10.1.4. 
Screening and Assessments/Procedures .....................................................................39 
10.2. 
Visit 2 (Baseline: Day 1) ............................................................................................41 
10.2.1. 
Pre-Randomization Assessments ................................................................................41 
10.2.2. 
Randomization Criteria ...............................................................................................41 
10.3. 
Visit 3 (Telephone Visit: Day 14) ..............................................................................42 
10.4. 
Visit 4 and 5 (Weeks 4 through 8) ..............................................................................42 
10.5. 
Visit 6 (Week 12) ........................................................................................................43 
10.5.1. 
Early Termination (ET) ..............................................................................................44 
10.5.2. 
Unscheduled Visits .....................................................................................................46 
10.6. 
Pharmacogenomic Assessment ...................................................................................46 
11. 
STUDY ASSESSMENTS ..........................................................................................47 
11.1. 
Screening Assessments ...............................................................................................47 
11.1.1. 
Psychiatric and Medical History .................................................................................47 
11.2. 
Efficacy Assessments .................................................................................................48 
11.2.1. 
Clinician-Administered PTSD Scale (CAPS-5) .........................................................48 
11.2.2. 
Montgomery-Åsberg Depression Rating Scale (MADRS) ........................................49 
11.2.3. 
Clinical Global Impression of Severity (CGI-S) ........................................................49 
11.2.3.1. 
CGI-S Assessments ....................................................................................................50 
11.2.4. 
Clinical Global Impression of Improvement (CGI-I) .................................................50 
11.2.4.1. 
CGI-I Assessments .....................................................................................................50 
11.2.5. 
Patient Global Impression of Change (PGIC) ............................................................50 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 13 of 84 
 
11.2.6. 
PROMIS Sleep (short form) Scale .............................................................................51 
11.2.7. 
Sheehan Disability Scale (SDS) .................................................................................51 
11.3. 
Safety Parameters .......................................................................................................51 
11.3.1. 
Adverse Events (AEs) .................................................................................................51 
11.3.2. 
Columbia-Suicide Severity Rating Scale (C-SSRS) ...................................................52 
11.3.3. 
Safety Planning Intervention (SPI) .............................................................................52 
11.3.4. 
Physical Examination .................................................................................................53 
11.3.5. 
Visual Examination of Oral Cavity ............................................................................53 
11.3.6. 
Vital Signs, Height and Weight ..................................................................................53 
11.3.7. 
Electrocardiogram (ECG) ...........................................................................................53 
11.3.8. 
Clinical Laboratory Assessments ...............................................................................53 
11.3.9. 
Pharmacogenomics Testing ........................................................................................55 
11.3.10. 
Assessment of Changes in Sexual Function: Changes in Sexual Functioning 
Questionnaire Short-Form (CSFQ-14) .......................................................................56 
12. 
DEFINITIONS, RECORDING, AND REPORTING OF ADVERSE 
EVENTS .....................................................................................................................56 
12.1. 
Definition of Adverse Events .....................................................................................56 
12.2. 
Adverse Event Recording ...........................................................................................56 
12.2.1. 
Coding the Adverse Event ..........................................................................................56 
12.2.2. 
Severity of Adverse Event ..........................................................................................57 
12.2.3. 
Relationship of Adverse Events to Study Drug ..........................................................57 
12.3. 
Serious Adverse Events (SAEs) and Serious Adverse Drug Reactions .....................57 
12.4. 
Pregnancy ...................................................................................................................59 
13. 
STATISTICS ..............................................................................................................59 
13.1. 
Populations for Analysis .............................................................................................60 
13.2. 
Estimate of Sample Size .............................................................................................60 
13.3. 
Assessment of Demographic and Baseline Characteristics ........................................60 
13.4. 
Efficacy Analysis ........................................................................................................60 
13.4.1. 
Efficacy Endpoints ......................................................................................................60 
13.4.2. 
Primary Efficacy Analysis ..........................................................................................62 
13.4.3. 
Secondary Efficacy Analyses .....................................................................................62 
13.4.4. 
Exploratory Analyses ..................................................................................................63 
13.5. 
Safety Analyses ..........................................................................................................63 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 14 of 84 
 
13.6. 
Interim Analyses .........................................................................................................63 
14. 
PROCEDURES FOR MODIFYING THE PROTOCOL OR 
TERMINATING THE STUDY .................................................................................64 
14.1. 
Protocol Modifications and Deviations ......................................................................64 
14.2. 
Study Termination ......................................................................................................64 
15. 
ETHICAL CONSIDERATIONS................................................................................64 
15.1. 
Ethical Conduct of the Study ......................................................................................64 
15.2. 
Ethics Committee/Institutional Review Board (EC/IRB) Review .............................65 
15.3. 
Written Informed Consent ..........................................................................................65 
16. 
DATA HANDLING AND RECORDKEEPING .......................................................66 
16.1. 
Maintaining Privacy and Confidentiality....................................................................66 
16.2. 
Maintaining Essential Clinical Documents ................................................................66 
16.3. 
Data Handling .............................................................................................................67 
16.4. 
Case Report Forms (CRFs) .........................................................................................67 
16.5. 
Screening Records ......................................................................................................68 
16.6. 
Clinical Laboratory Certification ................................................................................68 
16.7. 
Site Monitoring and Tonix’s Right to Review Records .............................................68 
16.8. 
Audits and Inspections ................................................................................................68 
17. 
CONFIDENTIALITY ................................................................................................69 
17.1. 
Protection of Patient Anonymity ................................................................................69 
17.2. 
Confidentiality of Study Information .........................................................................69 
17.3. 
Publication of Data and Protection of Trade Secrets ..................................................69 
18. 
LIST OF REFERENCES ............................................................................................71 
19. 
APPENDICES ............................................................................................................76 
APPENDIX 1. STUDY DESIGN AND SCHEDULE OF ASSESSMENTS .............................76 
APPENDIX 2. LIST OF CYP3A INHIBITORS ........................................................................79 
APPENDIX 3. AMRIX® PACKAGE INSERT (DATED APRIL 2019) ...................................80 
 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 15 of 84 
 
LIST OF TABLES 
Table 1: 
Clinical Laboratory Assessments ...............................................................................55 
Table 2: 
Medical Monitoring Contact Information ..................................................................59 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 16 of 84 
 
LIST OF FIGURES 
No table of figures entries found. 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 17 of 84 
 
4. 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
The following abbreviations and specialist terms are used in this study protocol. 
Abbreviation or 
Specialist Term 
Explanation 
AE 
Adverse Event 
ALT 
Alanine Aminotransferase 
ANCOVA 
Analysis of covariance 
AR 
Adrenoreceptors 
AST 
Aspartate Aminotransferase 
BMI 
Body Mass Index 
BOCF 
Baseline observation carried forward 
BPD 
Borderline Personality Disorder 
BUN 
Blood urea nitrogen 
CA-AF 
Criterion A – Assessment Form 
CAPS-5 
Clinician Administered PTSD Scale (for DSM-5) 
CBP 
Cyclobenzaprine 
CFR 
Code of Federal Regulations 
CGI-I 
Clinical Global Impression- Improvement (from Initiation of Treatment) 
CGI-S 
Clinical Global Impression of Severity 
CI 
Confidence Interval 
CMH 
Cochran–Mantel–Haenszel 
CNS 
Central Nervous System 
CoC 
Certificates of Confidentiality 
CPAP 
Continuous Positive Airway Pressure 
CRF 
Case Report Form 
CRO 
Contract Research Organization 
CSFQ-14 
Changes in Sexual Functioning Questionnaire Short Form 
C-SSRS 
Columbia Suicide Severity Rating Scale 
CYP3A4 
Cytochrome P450 subtype 3A4 
DSM-5 
Diagnostic and Statistical Manual of Mental Disorders (Version 5) 
e.g. 
Exempli gratia (for example) 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 18 of 84 
 
Abbreviation or 
Specialist Term 
Explanation 
EC 
Ethics Committee 
ECG 
Electrocardiogram 
eCRF 
Electronic case report form 
EEG 
Electroencephalogram 
ET 
Early Termination 
FDA 
Food and Drug Administration 
GCP 
Good Clinical Practice 
GLP 
Good Laboratory Practice 
HCl 
Hydrochloride 
HEENT 
Head, Eyes, Ears, Nose and Throat 
HIPAA 
Health Insurance Portability and Accountability Act 
HIV1 
Human immunodeficiency virus type 1 
HIV2 
Human immunodeficiency virus type 2 
i.e. 
id est (that is) 
IA 
Interim Analysis 
ICF 
Informed Consent Form 
ICH 
International Council on Harmonisation 
IDMC 
Independent Data Monitoring Committee 
IND 
Investigational New Drug 
IR 
Immediate-release 
IRB 
Institutional Review Board 
IUD 
Intrauterine device 
IWR 
Interactive Web Response 
 
 
LEC-5 
Life Events Checklist for DSM-5 
LOCF 
Last observation carried forward 
LS 
Least squared 
M.I.N.I. 
Mini International Neuropsychiatric Interview 
MCH 
Mean corpuscular hemoglobin 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 19 of 84 
 
Abbreviation or 
Specialist Term 
Explanation 
MCHC 
Mean corpuscular hemoglobin concentration 
mCPP 
meta-chlorophenylpiperazine  
MCV 
Mean corpuscular volume 
MDD 
Major Depressive Disorder 
Mg 
Milligram(s) 
MI 
Multiple imputation 
mITT  
Modified Intent-to-Treat 
MMRM 
Mixed Model Repeated Measures 
msec 
Millisecond(s) 
MSI-BPD 
McLean Screening Instrument for Borderline Personality Disorder 
N, n 
Number (of patients) 
NA 
Not applicable 
NDA 
New Drug Application 
NREM 
Non-rapid eye movement 
OEF 
Operation Enduring Freedom 
OIF 
Operation Iraqi Freedom 
OND 
Operation New Dawn 
PGIC 
Patient Global Impression of Change (Since Baseline) Scale 
PI 
Principal Investigator 
PO 
per os (by mouth) 
PRN 
pro re nata (as needed) 
PROMIS 
Patient-Reported Outcome Measurement Information System 
PSG 
Polysomnography 
PTSD 
Post-Traumatic Stress Disorder 
QTcF 
QT corrected for heart rate using Fridericia’s formula 
RBC 
Red blood cell 
REM 
Rapid eye movement 
SAE 
Serious Adverse Event 
SAP 
Statistical Analysis Plan 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 20 of 84 
 
Abbreviation or 
Specialist Term 
Explanation 
SD 
Standard deviation 
SDS 
Sheehan Disability Scale 
SE 
Standard Error 
SL 
Sublingual 
SOP 
Standard Operating Procedures 
SPI 
Safety Planning Intervention 
SWS 
Slow wave sleep 
TBI 
Traumatic brain injury 
TEAE 
Treatment Emergent Adverse Event 
TNX-102 SL  
Cyclobenzaprine HCl sublingual tablets 
Tonmya 
FDA conditionally accepted proposed proprietary name for TNX-102 
SL for the treatment of PTSD 
TSH 
Thyroid Stimulating Hormone 
TST 
Time Since Trauma 
US 
United States 
VA 
Veteran’s Administration 
WBC 
White blood count 
WHO 
World Health Organization 
 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 21 of 84 
 
5. 
INTRODUCTION 
TNX-102 SL is a tablet for sublingual administration containing cyclobenzaprine HCl [3-(5H-
dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine hydrochloride].  TNX-102 SL 
5.6 mg (2 x 2.8 mg tablets) are under development by Tonix Pharmaceuticals, Inc. (Tonix) as a 
treatment for posttraumatic stress disorder (PTSD). The proposed proprietary name for TNX-102 
SL (cyclobenzaprine sublingual tablets) for PTSD is Tonmya®. 
The active ingredient in TNX-102 SL, cyclobenzaprine HCl (CBP), has been approved for use in 
the United States (US) since 1977, originally as FLEXERIL® 10-mg oral tablets indicated as an 
adjunct to rest and physical therapy for the relief of muscle spasm associated with acute, painful 
musculoskeletal conditions.  The usual dose for this indication is 30 mg or 15 mg per day taken 
as 10 mg TID or 5 mg TID, respectively.  The FLEXERIL brand of immediate-release (IR) 
cyclobenzaprine tablets has been discontinued since May 2013.  Generic cyclobenzaprine is 
available and marketed in a variety of strengths including 5-, 7.5- and 10-mg IR tablets. 
AMRIX® (AMRIX® Prescribing Information, 2018), an extended-release capsule of 
cyclobenzaprine was approved in 2007 in the US as a New Drug Applications (NDA) and is 
currently available in 15- and 30-mg, taken once a day for the same indication as FLEXERIL in 
the US.  Both FLEXERIL and AMRIX are indicated for 2-3 weeks use only.  No 
cyclobenzaprine product has been approved for use in PTSD by Food and Drug Administration 
(FDA), Health Canada, or in any other country. 
As its primary pharmacologic action in relief of muscle spasm, cyclobenzaprine has been shown 
to decrease skeletal muscle hyperactivity in several animal models through central mechanisms 
involving blockade of either α2-adrenoreceptors (Barnes et al, 1980) (α2-AR) or serotoninergic 5-
HT2A receptors (Kobayashi et al, 1996; Honda et al, 2003).  Cyclobenzaprine acts primarily in 
the central nervous system (CNS) at the brain stem rather than at the spinal cord level, and does 
not act directly at the neuromuscular junction or directly on skeletal muscle. 
In addition to these primary pharmacologic actions, cyclobenzaprine has been observed to 
increase restorative sleep in fibromyalgia patients, which was correlated with improvement in 
daytime symptoms in a proof-of-concept study conducted by Vela Pharmaceuticals (Protocol No. 
VPI CY 0001.1) (Moldofsky et al, 2011) using low dose cyclobenzaprine (TNX-102 capsules).  
The rationale for testing cyclobenzaprine as a treatment for PTSD is based on known effects of 
cyclobenzaprine on CNS receptors and, in part, on the relationship of fibromyalgia and PTSD to 
disturbed and non-restorative sleep. 
PTSD is characterized by symptom clusters that include re-experiencing (intrusion) symptoms, 
avoidant behaviors, negative mood and cognitions, and heightened arousal and reactivity, the 
array of which develops and persists following exposure to a severely traumatic event.  It is well 
established that sleep disturbances are common among individuals with PTSD that has 
developed in response to combat traumas (Mellman et al, 1995; Pietrzak et al, 2010; Neylan et 
al, 1998) and sexual assault in civilians (Steine et al, 2012), as well as military sexual trauma 
(Kelly et al, 2011).  Among military personnel returning from OEF/OIF/OND deployments to 
Afghanistan and Iraq, sleep disturbances are considered the most frequent and severe of the 
PTSD symptoms (McLay et al, 2010).  Among all PTSD patients, civilian or military, sleep 
disturbances are considered core features of PTSD and are components of two of the main 
symptom clusters of PTSD including distressing dreams (re-experiencing cluster) and insomnia 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 22 of 84 
 
and restless sleep (hyperarousal cluster) (Krakow et al, 2001; Spoormaker et al, 2008).  Problems 
with sleep are not only thought to significantly exacerbate daytime symptoms of PTSD but also 
increase the likelihood of comorbid complications such as depression and substance use 
disorders as well as suicidal behaviors (Krakow et al, 2002; Saladin et al, 1995; Krakow et al, 
2000), a particularly critical problem in PTSD (Oquendo et al, 2003; Sareen et al, 2005).  
Moreover, because of a direct relationship between sleep disturbance in PTSD and suicidal 
ideation, it is suggested that targeting sleep disturbance may help prevent suicidal behaviors in 
PTSD (Betts et al, 2013). 
A growing body of evidence suggests that sleep disruption plays an important causal role in the 
pathogenesis of PTSD (Koren et al, 2002; Mellman et al, 2002; McLay et al, 2010; Wright et al, 
2011).  Moreover, sleep disturbance is a frequent residual complaint after successful PTSD 
treatment, a finding that applies to both psychological and pharmacological treatment 
(Spoormaker et al, 2008).  Evidence is now emerging that pharmacological targeting of sleep 
disturbance in PTSD, in which self-reported and polysomnographic improvement in sleep 
parameters is achieved, can account for over 90% of the variance in improvement in PTSD 
severity ratings and work/school function (Krystal et al, 2013). 
Understanding of PTSD pathophysiology has been greatly advanced due to heuristic models of 
trauma based on animal work on fear conditioning and extinction (Yehuda & LeDoux, 2007; 
Maren et al, 2013).  Human studies of fear memory and stress responsiveness have highlighted 
the potential role of sleep, particularly rapid eye movement (REM) sleep, in affective and 
memory processes (Pace-Schott et al, 2015; Yoo et al, 2007; Pace-Schott et al, 2009).  There is 
evidence for the hypothesis that sleep disturbances play a critical role in PTSD by compromising 
sleep-dependent affective and memory processing that may be key for recovery from PTSD 
(Yehuda & LeDoux, 2007). 
5.1. 
Sleep and PTSD 
Subjective sleep disturbance, characterized by non-restorative sleep, frequent awakenings and 
distressing dreams and nightmares related to the trauma, is a core feature of PTSD (Spoormaker 
et al, 2008).  Clinical observations focusing on the nature of sleep complaints suggest 
dysregulation in both REM and non-rapid eye movement (NREM) sleep in PTSD (Woodward et 
al, 2000; Germain et al, 2013).  Meta-analysis of polysomnography (PSG) studies in both 
military veterans and adult civilians suggest modest indices of sleep disruption in PTSD using 
these traditional measures, with greater stage 1 (light) sleep, reduced slow wave sleep (SWS), 
and greater REM density compared with individuals without PTSD (Kobayashi et al, 2007). 
Quantitative EEG, in which high frequency beta and gamma activity are considered indices of 
central arousal during sleep, has indicated both greater beta activity during NREM and lesser 
beta activity during REM sleep in PTSD, as well as disturbances in delta activity, and heart rate 
differences between REM and NREM related to the amount of REM sleep (Woodward et al, 
2002; Neylan et al, 2003; Halász et al, 2004; Woodward et al, 2000).  Such changes are 
consistent with the pathophysiology of PTSD, which involves hypervigilance and exaggerated 
responses to both external and internal stimuli, and which are putatively indicative of heightened 
nocturnal sympathetic noradrenergic activity (Berridge et al, 2012; Breslau et al, 2005; Capaldi 
et al, 2011). 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 23 of 84 
 
A recent evaluation of treatment algorithms for PTSD found that addressing fragmented sleep 
and nightmares consistently improves all symptom domains in PTSD, such that targeting sleep-
related symptoms has been recommended as an initial step for treatment of all patients with 
PTSD (Bajor et al, 2011).  Prazosin, a centrally acting α1-adrenoreceptor antagonist, has been 
repeatedly demonstrated to provide improvements on subjective measures of sleep disturbance 
and PSG in both civilian and combat related trauma (Raskind et al, 2003; Taylor et al, 2008; 
Raskind et al, 2007; Raskind et al, 2013).  It is notable that prazosin treatment has also been 
reported to improve non-sleep symptoms in PTSD (Taylor et al, 2006; Raskind et al, 2007), 
however, a recently reported large (N=304) multicenter VA cooperative study (#563) failed to 
show improvement on total CAPS score with prazosin (Raskind et al 2018).  
Normal NREM sleep is associated with a reduction in sympathetic nervous system drive and 
increase in parasympathetic nervous system drive (Berridge et al, 2012; Pace-Schott et al, 2015).  
In PTSD, there is evidence that the nocturnal secretion of norepinephrine remains high, which 
could be a factor resulting in fragmented REM sleep.  Since cyclobenzaprine shares α1-
adrenoreceptor antagonist activity with prazosin, cyclobenzaprine may have similar therapeutic 
effects on sleep disturbances in PTSD based on this molecular target. 
In addition to the efficacy evidence demonstrated in the TNX-102 SL Phase 2 study 
(Section 5.1.1), the potential clinical utility of cyclobenzaprine in treating PTSD is also 
supported by the promising results of studies with agents that share a molecular mechanism of 
antagonism of the 5-HT2A receptor (Hertzberg et al, 1996; Warner et al, 2001; Davidson et al, 
1998; Hertzberg et al, 1998; Hidalgo et al, 1999; Davis et al, 2004; Connor et al, 1999; Bahk et 
al, 2002; Kim et al, 2005; Lewis, 2002; Davidson et al, 2003).  The 5-HT2A blocking activity of 
cyclobenzaprine may be crucial to the aforementioned enhancement of sleep-dependent memory 
processing believed to be necessary for recovery from PTSD (Datta & O’Malley 2013; Karshima 
et al, 2010; Siwek et al, 2014; Datta et al, 2008).  Another of cyclobenzaprine’s high affinity 
receptors, also where it acts as an antagonist, is the H1 receptor, which has been shown to have 
antianxiety effects (Llorca et al, 2002), play a role in wake promotion (Monti et al 2011; Huang 
et al, 2006), and has been implicated in emotional processing (Serafim et al, 2012, 2013) known 
to be sleep-dependent.  Thus, in summary, the pharmacodynamic profile of cyclobenzaprine’s 
CNS receptor activities appears well-suited for treating PTSD based on its potential to combine 
the activities on sleep and emotional memory processing of the α1-adrenergic receptor antagonist 
prazosin, 5-HT2A receptor antagonist antidepressants, and histaminergic H1 antagonists. 
5.1.1. 
Brief Summary of Prior Clinical Experience, Dose Rationale and Justification of 
Study Design 
 
 
 
 
 
 
 
 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 24 of 84 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 25 of 84 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
  
 
 
 
 
 
 
 
 
   
 
 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 26 of 84 
 
6. 
TRIAL OBJECTIVES AND PURPOSE 
6.1. 
Primary Objective 
To evaluate the efficacy of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) in the 
treatment of PTSD. 
6.2. 
Secondary Objectives 
To evaluate the safety of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) in the treatment 
of PTSD. 
7. 
INVESTIGATIONAL PLAN 
7.1. 
Overall Study Design 
This is a Phase 3, 12-week, randomized, multicenter, double-blind, placebo-controlled, fixed 
dose study that will investigate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg 
tablets) taken daily at bedtime for the treatment of PTSD.  This study is to be conducted at 
approximately 25-30 investigational sites in the United States. 
The total duration of this study over 6 visits will be approximately 13-15 weeks, with 12 weeks 
of treatment duration and a variable length of screening.  This study will consist of a Screening 
visit (Visit 1, Days −21 to −7, Randomization visit (Visit 2, Day 1), telephone visit (Visit 3, 
Week 2) and three monthly in-clinic visits (Visits 4, 5,  and 6 at Weeks 4, 8, and 12, 
respectively). 
Eligible patients who provide written informed consent to participate will have study 
assessments performed at Screening, including counseling regarding any required washout and 
instructions to refrain from use of excluded medications throughout the study. 
The length of the pre-randomization screening period is variable (7 to 21 days) in order to 
accomplish wash-out of previous medications, where appropriate, and allow for return of clinical 
laboratory results necessary to confirm eligibility.  At Visit 2, patients will return to the site for 
additional baseline assessments and randomization (Day 1), when, if they meet all study 
randomization criteria, they will be randomly assigned in a 1:1 ratio to receive TNX-102 SL 5.6 
mg or placebo.  Randomization will be stratified based on investigative site and sex.  Patients 
will take the study drug sublingually daily at bedtime, starting on the day that they are 
randomized and continuing for 12 weeks (or to early termination).   
Patients who test positive for cocaine, ecstasy (MDMA), methamphetamine or other non-
disclosed illicit drugs (other than marijuana) should be screen-failed.  In addition, patients who 
meet M.I.N.I. criteria outlined in the entry criteria for alcohol/substance use disorder over the 6 
months prior to Screening should be screen-failed, i.e. greater than mild alcohol use or substance 
use disorder. 
NOTE:  Patients who use alcohol/marijuana but do not meet criteria for greater than mild 
alcohol/substance use disorder (per Diagnostic and Statistical Manual of Mental Disorders 
[Version 5; DSM-5]) are otherwise suitable for the study provided that, in the judgment of the 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 27 of 84 
 
Investigator, this usage will not interfere with the patient’s ability to complete the study or 
provide reliable data.  Information related to marijuana and alcohol use will be collected at 
Screening. 
Patients suffering from depression are eligible for the study, provided their depression does not 
pose an undue risk to their well-being (e.g., high suicidal risk) or of a severity warranting 
treatment with antidepressants or other excluded treatments.  The investigator will evaluate each 
patient’s medical and psychiatric history, current symptomatology, and the results of the M.I.N.I 
7.0.2, MADRS, C-SSRS, and CAPS-5 from Visits 1 and 2, to determine whether it is appropriate 
for the patient to participate in the study.  Patients scoring >26 on the screening MADRS who 
the Investigator thinks appropriate for randomization will undergo Medical Monitor pre-
randomization review to ensure agreement with the investigator’s assessment.   
Patients with evidence of hepatic impairment secondary to hepatitis B or C at screening, or who 
are undergoing treatment for hepatitis, should be excluded.  Patients with stable and 
asymptomatic disease whose hepatic enzymes (aspartate aminotransferase [AST] or alanine 
aminotransferase [ALT]) satisfy the study’s entry criteria (< 3 times the upper limits of normal), 
may be allowed to proceed with randomization with prior Medical Monitor approval. 
CAPS-5, M.I.N.I. 7.0.2 and Columbia Suicide Severity Rating Scale (C-SSRS) interviews will 
be conducted by an approved and qualified individual(s) at each site who has successfully 
completed training on each instrument. 
If a patient scores a 2 or 3 on the suicidal ideation section of the C-SSRS at any visit (including 
the Screening visit), the investigator and patient should work together to implement a Safety 
Planning Intervention (SPI).  As described in detail in Section 11.3.3, the recommended SPI for 
this study is the plan developed by Barbara Stanley, PhD and Gregory Brown, PhD which has 
been adopted by the U.S. Veteran’s Administration (VA) (Stanley & Brown, 2012).  The SPI is a 
brief clinical intervention aimed at mitigating suicide risk.  It consists of a written, prioritized list 
of coping strategies and sources of support that patients can use to alleviate a suicidal crisis.  
Sites may use an internally-developed SPI if similar in scope and purpose to the SPI adopted by 
the VA. 
The study timeline and events schedule is provided in Appendix 1. 
7.2. 
Number of Patients and Treatment Assignment 
A total of approximately 250 patients will be randomized in a 1:1 ratio to treatment with TNX-
102 SL 5.6 mg (2 x 2.8 mg) tablets or identical SL placebo tablets.  See Section 13.2 for details 
regarding potential sample size adjustment. 
7.3. 
Study Endpoints 
7.3.1. 
Primary efficacy endpoint 
The primary efficacy endpoint will be the mean change from baseline (Visit 2) in the total 
Clinician Administered PTSD Scale-Version 5 (CAPS-5) score evaluated at Week. 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 28 of 84 
 
7.3.2. 
Secondary efficacy endpoints 
7.3.2.1. 
Key Secondary Efficacy Endpoints 
The efficacy endpoints listed below are considered key secondary endpoints and will be tested in 
the following order: 
• Change from baseline to Week 12 in CGI-S. 
• Change from baseline to Week 12 in the SDS total score. 
• Change from Baseline to Week 12 in the PROMIS Sleep Disturbance total score 
A fixed sequence procedure will be applied to the key secondary efficacy endpoints to adjust for 
multiplicity and to control for overall type I error. 
7.3.2.2. 
Other Secondary Efficacy Endpoints 
• Change from baseline to Week 12 in the disruption of work/school activities assessed 
using the SDS. 
• Change from baseline to Week 12 in disruption of social life/ leisure activities 
assessed using the SDS. 
• Change from Baseline to Week 12 in the disruption of family life/home 
responsibilities assessed using the SDS. 
• Change from baseline to Week 12 in CAPS-5 Arousal and Reactivity (Criterion E) 
score. 
• Change from baseline to Week 12 in CAPS-5 Intrusion symptoms (Criterion B) 
score. 
• Change from baseline to Week 12 in CAPS-5 Negative Cognition and Mood 
(Criterion D) score. 
• Change from baseline to Week 12 in CAPS-5 Persistent Avoidance (Criterion C) 
score. 
• Change from baseline to Week 12 in CAPS-5 Sleep Disturbance (item E-6) score. 
• Change from Baseline to Week 12 in CGI-I. 
• Change from Baseline to Week 12 in mean PGIC score. 
• Proportion of patients with a treatment response on the CGI-I defined as a CGI-I 
score of “much improved” or “very much improved” at Week 12. 
• Proportion of patients with a PGIC score of “much improved” or “very much 
improved” at Week 12.  
• Proportion of patients with a Total CAPS-5 score of 0 –10 (asymptomatic/few 
symptoms) at Week 12. 
• Proportion of patients with a Total CAPS-5 score of 0-22 (asymptomatic or mild 
PTSD/subthreshold) at Week 12. 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 29 of 84 
 
• Proportion of patients with Response, defined as a ≥ 10-point improvement from 
baseline at Week 12 in Total CAPS-5 score. 
• Proportion of patients with Loss of Diagnosis, defined as Response AND no longer 
meeting DSM-5 symptom criteria in any one or more of the four clusters (B, C, D, E) 
at Week 12. 
• Proportion of patients in Remission, defined as Loss of Diagnosis AND Total CAPS-
5 score ≤ 10 at Week 12. 
• Proportion of patients achieving sustained Remission, defined as Loss of Diagnosis 
AND Total CAPS-5 score ≤ 10 after both 8 weeks AND 12 weeks of treatment.  
• Proportion of patients with a ≥30% reduction from baseline to Week 12 in Total 
CAPS-5 score. 
• Proportion of patients with a ≥50% reduction from baseline to Week 12 in Total 
CAPS-5 score. 
• Change from baseline to Week 12 in MADRS score. 
• Change from baseline to Week 12 in CAPS-5 Reckless or Self-Destructive Behavior 
(item E-2) score.  
• Changes from baseline in patient-rated Changes in Sexual Functioning Questionnaire 
Short-Form (CSFQ-14) in males and in females, analyzed separately 
 
7.3.3. 
Exploratory efficacy endpoints 
Any exploratory endpoints will be delineated in the Statistical Analysis Plan (SAP). 
7.3.4. 
Safety 
Safety will be assessed by: 
• Adverse events (AE) and serious AEs (SAEs) throughout the entire duration of the 
study, including detailed assessment of AEs involving the oral cavity 
• Changes from baseline in clinical laboratory test results 
• Changes from baseline in vital signs and weight 
• Change from baseline in MADRS score 
• Changes from baseline indicative of increased suicidal ideation or behavior as 
assessed by the Columbia Suicide Severity Rating Scale (C-SSRS) 
• Changes from baseline in patient-rated Changes in Sexual Functioning Questionnaire 
Short-Form (CSFQ-14) in males and in females, described separately 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 30 of 84 
 
7.4. 
Efforts to Minimize Missing Data 
It is important to avoid missing data from clinical trials.  The following strategies are designed to 
minimize drop-outs and missing data in this study: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8. 
SELECTION AND WITHDRAWAL OF PATIENTS 
8.1. 
Informed Consent 
A potential patient may be screened for eligibility only after the nature of the study, its purpose, 
and any other information relevant to the patient’s decision to participate have been explained to 
him or her and the patient has voluntarily confirmed his or her willingness to participate.  If 
medications are to be withdrawn for the explicit purpose of participation in this study, the patient 
must first sign an informed consent form before the withdrawal or down titration of any 
medication is initiated. 
Informed consent is documented by means of a written, signed, and dated informed consent form 
(ICF). Separate written, signed informed consent must be obtained if the patient is to participate 
in the optional pharmacogenomic assessment. Additional information is provided in 
Section 15.3. 
8.2. 
Inclusion Criteria 
Patients enrolled in this study will be volunteer patients.  Eligible patients must meet all of the 
following inclusion criteria during the screening period: 
1. Male or female between 18 and 75 years of age, inclusive.  

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 31 of 84 
 
2. Diagnosed with current PTSD as determined by the Clinician-Administered PTSD Scale 
(CAPS-5) for Diagnostic and Statistical Manual of Mental Disorders-Version 5 (DSM-5) 
and of sufficient symptom severity, defined as all of the following at Screening Visit 1 
using the Diagnostic version (1-month recall): 
a. The A criterion is 1=YES, and 
b. At least ONE item of the B criterion items must have a score of ≥2, and 
c. At least ONE item of the C criterion items must have a score of ≥2, and 
d. At least TWO items of the D criterion items must have a score of ≥2, and 
e. At least TWO items of the E criterion items must have a score of ≥2, and  
f. The F item 22 criterion is 1=YES (≥1-month duration of symptoms) 
g. At least ONE item of the G items must have a score of ≥2, and 
h. The total CAPS-5 score (of items 1 through 20 is) ≥29. 
3. Index trauma(s) resulting in PTSD must meet the following: 
a. DSM-5 criterion A for PTSD as described in the CAPS-5 and Criterion A – 
Assessment Form (CA-AF), and 
b. Must have occurred within 9 years of Screening Visit 1, and  
c. Must have occurred ≥ 3 months prior to the Screening Visit, and 
d. Must have occurred when the patient was ≥18 years of age.  
4. Willing and able to withdraw and refrain from opioids for the course of the study. 
5. Willing to refrain from use of all other formulations of cyclobenzaprine for the course of 
the study. 
6. Willing and able to refrain from antidepressants, antipsychotics, mood stabilizers, 
anticonvulsants, benzodiazepines, non-benzodiazepine hypnotics, buspirone, stimulants 
(e.g. amphetamines, methylphenidate, modafinil, armodafinil), prazosin and trazodone 
for the course of the study. 
7. Capable of reading and understanding English and able to provide written informed 
consent to participate. Separate written, signed informed consent will be required if the 
patient is to participate in the optional pharmacogenomic assessment. A decision not to 
participate in optional pharmacogenomic testing will not affect the subject’s eligibility 
for the main study. 
8. If female, either not of childbearing potential (defined as postmenopausal for at least one 
year or surgically sterile [e.g., bilateral tubal ligation; bilateral oophorectomy; 
hysterectomy, etc.]) or practicing one of the following medically acceptable methods of 
birth control throughout the study: 
a. Hormonal methods such as oral, implantable, injectable, or transdermal 
contraceptives for a minimum of one full cycle (based on the patient’s usual 
menstrual cycle period) before study drug administration; 
b. Intrauterine device (IUD); 
c. Double-barrier method (condoms, sponge, diaphragm, or vaginal ring with 
spermicidal jellies or cream); 
d. In sexually-exclusive relationship with vasectomized male partner, or in same-sex 
relationship with no plans for artificial or other forms of insemination. 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 32 of 84 
 
9. Willing and able to comply with all protocol-specified requirements. 
10. If patient has received trauma-focused treatment (e.g., cognitive behavioral therapy for 
PTSD, prolonged exposure therapy, desensitization therapy, etc.) must have been 
completed at least three months prior to the Baseline visit, and there can be no plans to 
initiate this type of therapy during study.  General psychotherapy that was in process at 
time of Screening may be continued during the trial, but no new initiation of treatment is 
allowed during the trial after enrollment. 
8.3. 
Exclusion Criteria 
Eligible patients who meet any of the following criteria during the screening period should be 
excluded from the study: 
1. Current or ongoing exposure to the trauma that resulted in the PTSD. 
2. Increased risk of suicide on the basis of the Investigator’s judgment and/or the results of 
the Mini International Neuropsychiatric Interview, Version 7.0.2 (M.I.N.I. 7.0.2) 
conducted at Screening and the Columbia Suicide Severity Rating Scale (C-SSRS) 
conducted at Screening and/or Baseline and Item 10 of the Montgomery-Åsberg 
Depression Rating Scale (MADRS) at Screening and/or Baseline. Any of the following 
will be exclusionary: 
a. High suicidality based on a M.I.N.I. Module B score ≥ 17 (Screening); or, 
b. Patient answers YES to either M.I.N.I. question B10 or B11 (Screening); or, 
c. Patient meets criteria for CURRENT Suicidal Behavior Disorder on the M.I.N.I 
(Screening); or, 
d. C-SSRS Type 4 or Type 5 ideation within 6 months of Screening or at the 
Baseline visit; or,  
e. Any suicidal behavior in the past 12 months as identified by the C-SSRS at 
Screening or Baseline. 
f. A score of > 4 on Item 10 of the MADRS at Screening or Baseline. 
3. Increased risk of suicide, based on the Investigator’s judgment that is of a severity that is 
not appropriate for outpatient management, or that warrants additional therapy excluded 
by the protocol. 
4. Significant (e.g., moderate or severe) comorbid traumatic brain injury (TBI) by history.   
Based on past history and Investigator’s judgment, patients with mild TBI are eligible. 
5. Severe depression suggested by a Screening (Visit 1) MADRS score > 26.   Patients with 
a Screening MADRS score of > 26 may be randomized upon Medical Monitor approval, 
based on a review of all Screening rating scales and the patient’s psychiatric/medical 
history.         
6. Clinically significant laboratory abnormalities based on screening laboratory tests and/or 
medical history in the Investigator’s opinion, including a Thyroid Stimulating Hormone 
(TSH) level > 1.5 times the upper limit of normal and aspartate aminotransferase (AST) 
and/or alanine aminotransferase (ALT) > 3 times the upper limit of normal (if persistent 
upon repeat).  Patients with treated thyroid conditions and TSH levels < 1.5 times the 
upper limit of normal will be eligible to participate in the study. 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 33 of 84 
 
7. Diagnosed with clinically significant and currently relevant cardiac disease (e.g., 
significant arrhythmia or heart block, heart failure) or recent myocardial infarction 
[within the past 2 years]) or QTcF > 450 msec (male) or > 470 msec (female) on the 
screening electrocardiogram (ECG). 
8. Current evidence of human immunodeficiency virus (HIV) infection based on screening 
laboratory results or medical history, or clinically significant hepatitis B or C infection as 
defined by current treatment or liver function tests (e.g., aspartate aminotransferase 
[AST] or alanine aminotransferase [ALT] > 3 times the upper limits of normal). 
9. Use of antidepressant medication within 2 months of baseline, with the exception of 
trazodone used at doses ≤ 150 mg per day or tricyclic antidepressants at doses ≤ 50 mg 
per day for the purpose of treating insomnia, which instead require a 1-week drug-free 
interval prior to the Baseline visit. 
10. Unable to successfully wash out of the following medications during screening, or in 
whom washout is medically inadvisable: anticonvulsants, mood stabilizers, anti-psychotic 
agents, opioids, benzodiazepines, non-benzodiazepine hypnotics (zolpidem, eszopiclone, 
zaleplon), buspirone, trazodone, stimulants (e.g., amphetamine mixed salts, 
methylphenidate, lisdexamphetamine, dextroamphetamine, modafanil, armodafanil), 
atomoxetine,  or any medication known to be a potent (strong) cytochrome P450 subtype 
3A4 (CYP3A4) inhibitor, or St. John’s wort.  Note:  Use of caffeine and/or nicotine is 
permitted. 
11. Unable to successfully wash out of alpha-adrenergic antagonists and/or agonists (e.g., 
prazosin, terazosin, doxazosin, tamsulosin, silodosin, tizanidine, clonidine, guanfacine) or 
when washout is medically inadvisable. 
12. Positive results for illegal or abused substances other than cannabis at Screening or 
Baseline or history of alcohol/substance use disorder during the preceding 6 months as 
defined by the screening M.I.N.I. 7.0.2.  Patients who utilize alcohol and/or cannabis but 
do not meet criteria for greater than MILD alcohol and/or substance use disorder are 
suitable for the study provided that, in the judgment of the Investigator, this usage will 
not interfere with the patient’s ability to complete the study or provide reliable data. 
13. Any clinically significant, uncontrolled, or unstable medical or surgical condition that 
could affect a patient’s ability to participate in the study or potentially compromise a 
patient’s well-being during the study, including patients with a history of untreated or 
uncontrolled angle-closure glaucoma.   
14. Diagnosis of DSM-5-defined bipolar disorder I, II or unspecified, schizophrenia, 
schizoaffective disorder, obsessive-compulsive disorder, major depressive disorder 
(MDD) with psychotic features, other psychotic disorder, or antisocial personality 
disorder as confirmed by the M.I.N.I. Version 7.0.2. 
15. History of or evidence for a diagnosis of borderline personality disorder (BPD) based on 
a score of ≥ 7 on the McLean Screening Instrument (MLI) for BPD at Visit 1 (Screening) 
and Investigator determination that the rated symptoms of BPD are not simply due to 
overlap with PTSD symptomatology.  Patients who score ≥ 7 on the MLI may be 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 34 of 84 
 
randomized upon Medical Monitor approval if the high score does appear to be a result of 
overlap of PTSD symptoms rather than presence of BPD. 
16. Anticipated need for surgery that might confound results or interfere with patient’s ability 
to comply with the protocol. 
17. Female patients who are pregnant or lactating. 
18. History of serotonin syndrome, severe allergic reaction or bronchospasm or known 
hypersensitivity to cyclobenzaprine or the excipients in TNX-102 SL or placebo 
formulations. 
19. Seizure disorder other than history of childhood febrile seizures. 
20. Current sleep apnea not well controlled by Continuous Positive Airway Pressure (CPAP) 
or oral (mouthpiece) devices.  Patients with mild obstructive sleep apnea or those well 
controlled by CPAP or oral (mouthpiece) devices are allowed at the discretion of the 
Investigator. 
21. Patients with a body mass index (BMI) > 40. 
22. Has received any other investigational drug within 90 days before Screening or has taken 
cyclobenzaprine within 21 days before Randomization visit. 
23. Previous participation in any other study with TNX-102 SL. 
24. Any existing oral medical or dental condition, or tongue piercings, that could potentially 
interfere with sublingual administration of study drug, or history of severe or unexplained 
oral or oropharyngeal swelling or edema. 
25. Family member of investigative staff. 
26. In the process of litigating for compensation for a psychiatric disorder.   
8.4. 
Randomization Criteria 
The following randomization criteria must be satisfied at the Visit 2 Baseline Randomization 
Visit in order for the patient to be eligible to continue in the study.  Only those patients meeting 
all of the following randomization criteria are eligible for randomization: 
1. Patient continues to meet all inclusion and exclusion criteria, including urine and 
blood test results, and 
2. Visit 2 total CAPS-5 score ≥ 33 (“Symptom Severity version using 1-week recall), 
and 
3. No active suicidal intent or plan, or suicidal behavior, based on Investigator’s 
judgment and Visit 2 C-SSRS responses (e.g., no C-SSRS Type 4-5 ideation or 
suicidal behavior since Visit 1) and/or a score of > 4 on Item 10 of the Visit 2 
MADRS. 
8.5. 
Prior and Concomitant Medications 
Many concomitant psychiatric medications are prohibited during this study because this study 
has been designed to evaluate the safety and efficacy of monotherapy with TNX-102 SL tablets 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 35 of 84 
 
for the treatment of PTSD.  The goal of the study is to recruit patients who are not currently 
using other medications to treat their PTSD, or who are not clearly benefitting from any of the 
medications that would need to be discontinued in order to enter this study.  Since many patients 
with PTSD may already be taking one or more excluded medications when screened, Principal 
Investigators should use extreme caution when determining whether a patient, in their clinical 
judgment, can be safely withdrawn from current medications that are being used to treat PTSD or 
are otherwise excluded from the protocol. 
Eligible patients will not be receiving treatment with antidepressants, antipsychotic agents, mood 
stabilizers or anticonvulsants.  In addition, eligible patients will not have taken antidepressants 
within 2 months of the Baseline visit.  This time frame is intentionally long because it is not 
considered appropriate for patients to discontinue antidepressants solely to enter the study.  An 
exception is made for the use of low-dose tricyclic agents at doses ≤ 50 mg per day, or trazodone 
at doses ≤ 150 mg per day for the purpose of treating insomnia, either of which may be 
discontinued for the purpose of enrollment but requires a 1-week medication-free period prior to 
randomization, as described below. 
Patients also must be willing and able to discontinue use of benzodiazepines, non-
benzodiazepines and certain other medications frequently used to treat PTSD; e.g., prazosin; 
trazodone; topiramate.  Discontinuation of any of these agents should only be considered if/when 
the patient’s clinical condition and stability will not be adversely affected. 
Unless otherwise stated, excluded medications (e.g., trazodone, prazosin, topiramate, alpha- 
adrenergic agonists or antagonists [e.g., prazosin; tamsulosin; terazosin; doxazosin, silodosin, 
alfuzosin, clonidine, guanfacine], buspirone, benzodiazepines, and non-benzodiazepine 
hypnotics [zolpidem, zaleplon, eszopiclone]) will require a 1-week drug-free period prior to the 
Baseline visit (Visit 2).  Several benzodiazepines are not easily detected by the in-clinic urine 
dipstick; therefore, any patient whose screening UDS is positive for benzodiazepines should 
undergo repeat urine testing after washout, and that sample should be sent to the central 
laboratory for centralized interpretation. Because of this, the Baseline visit may need to be 
delayed to provide sufficient time for the results of the repeat, post-washout drug screen to be 
returned to the site, since the patient should not be randomized until negative results have been 
confirmed. It is recommended that the Baseline visit is scheduled no sooner than 7 days after the 
patient’s post-washout urine drug screen, to ensure the results are available for review at the 
Baseline visit.  
 
Similarly, all opioid medications, including tramadol and tapentadol, are excluded medications.  
Patients on chronic opioids are not appropriate candidates for participation, but there may be 
patients with occasional PRN opioid usage or who were recently on a short course for acute pain 
who may be appropriate if, in the clinical judgement of the Investigator, they could be safely 
tapered and remain opioid free for the week before baseline visit and throughout the 12 weeks of 
the study.  The screening period of up to 21 days is provided to ensure a safe tapering rate and 
discontinuation of excluded medications, per Investigator’s discretion, leading up to the 1-week 
medication-free period required before the randomization/baseline visit. 
Other medications capable of modifying the pharmacologic activity of TNX-102 SL (e.g., α-
adrenergic agonists/antagonists; potent CYP3A4 inhibitors) will also be excluded, and 
discontinuing these medications should only be considered if clinically acceptable.  A list of 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 36 of 84 
 
CYP3A4 inhibitors is provided in Appendix 2; only those considered potent or strong inhibitors 
(in the left-hand column) are excluded medications.   
8.5.1. 
Allowed Concomitant Medications 
It is ideal to have all patients participating in the study go without any hypnotic agents for the 
entire double-blind period of the study.  Yet there may be instances in which patients’ insomnia 
symptoms need to be addressed with a concomitant treatment.  In these instances, the 
Investigator should recommend use of an antihistamine-based OTC hypnotic, such as Benadryl® 
or generic diphenhydramine 25-50 mg, for a limited period (e.g. no more than a few nights in a 
row).  Patients should be asked to keep track of their use of such sleeping remedies, and again, 
chronic nightly use should be avoided whenever possible.   
Melatonin is considered an allowable concomitant medication but its usage should have been 
stable for at least 30 days prior to baseline and usage should remain stable during the study.  If 
diphenhydramine is ineffective, the treating Investigator should contact the medical monitor to 
discuss alternative options.    
Allergy medications and cold remedies containing adrenergic agonist decongestants such as 
pseudoephedrine or phenylephrine should be avoided unless absolutely necessary (and in such 
cases when considered absolutely necessary, they should be avoided in the evening or at bedtime 
to minimize their interference with sleep).  Sympathomimetics such as adrenergic agonist 
decongestants have the potential to acutely worsen PTSD symptoms and therefore could 
confound the assessment of TNX-102 SL versus placebo for treatment of PTSD. 
Other prescription or over-the-counter medications not specifically excluded by entry criteria 
typically may be continued during the study, with the expectation that chronic medications 
should have been used in a stable fashion for at least 30 days prior to randomization.  Sites 
should contact the medical monitor for any questions about whether a concomitant medication 
may be continued during the study or if it would be acceptable to taper an excluded medication. 
8.6. 
Withdrawal Criteria 
In accordance with the Declaration of Helsinki, human patients have the right to withdraw from 
the study at any time for any reason.  The investigator and Tonix also have the right to remove 
patients from the study.  Additional information regarding withdrawal or discontinuation of 
patients is described in detail in Section 10.5.1. 
9. 
STUDY DRUG MATERIALS AND MANAGEMENT 
9.1. 
Study Drug Packaging, and Labeling and Storage 
Study drug supplies will be packaged identically so as to maintain the integrity of the study 
blind.  The study medication bottles will be labeled minimally with the following information:  
study number TNX-CY-P302, sponsor name and address, bottle number, quantity, storage 
conditions, usage instructions, and caution statements for investigational new drug, i.e., Caution: 
New Drug – Limited by United States Law to Investigational Use, and Keep Out of Reach of 
Children and Pets. 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 37 of 84 
 
Each study medication bottle will contain 40 tablets.  Two bottles will be dispensed to each 
patient at Visit 2 (baseline), Visit 4 (Week 4),  and Visit 5 (Week 8); this will provide the patient 
with 80 tablets to cover the 4 weeks of dosing between visits, plus additional tablets to cover loss 
and/or visit window variability.  The patient should be instructed to take all the tablets in one 
bottle before opening the second bottle.  The patient should be instructed to keep this study 
medication in a safe location out of extreme environmental conditions and out of the reach of 
children and pets, and be instructed that this medication is not to be taken by any individual other 
than the study patient.  Each patient will also be instructed that they will be expected to return 
both bottles and all unused study medication at each clinic visit; unused medication will be 
counted to assess compliance with study drug treatment. 
Storage of the study drug at the investigational site should be under locked and secure conditions 
with limited staff access.  Study drug should be stored at 20-25°C/68-77°F in a 
temperature/humidity-monitored room; however, brief excursions (15-30°C/59-86°F) as defined 
in the Study Reference Manual (IP Receipt and Storage) are permitted without the sponsor’s 
approval. 
9.2. 
Dosing Instructions 
Patients will be instructed to take two tablets of their assigned study drug (TNX-102 SL 2.8 mg 
tablets or placebo tablets) sublingually, placed simultaneously under the tongue, each evening 
at bedtime starting at bedtime on evening of Day 1 (Day of Visit 2) and continuing without 
interruption for 12 weeks.  The study drug should be taken at bedtime after teeth brushing and 
other oral care has been completed.  The mouth/sublingual area should be moist at the time of 
dosing, so the patient should drink a few sips of water prior to dosing, especially if prone to dry 
mouth.  Patients will be instructed to place the two SL tablets under their tongue and keep them 
there until they have dissolved.  They should not swallow, crush or chew the tablets.  Patients 
should not eat or drink (or chew gum) for at least 15 minutes after dosing, and preferably not 
until morning.  Patients will be reminded that only 2 (two) tablets are allowed per day. Note:  In 
the event that the patient misses a dose, instruct the patient to continue dosing with two (2) 
tablets the next evening; i.e., they should not take more to make up for the missed dose. 
9.3. 
Dispensing Instructions 
Each patient who has met the randomization criteria (Section 8.3) will be assigned 2 double-
blind treatment bottles at Visit 2 via the IWRS, with a unique, but otherwise random bottle 
number that is generated when the study coordinator successfully completes randomization 
procedures.  Patients will also be assigned two new treatment bottles at Visits 4 and 5 via the 
IWRS.  The bottle numbers provided by the Interactive Web Response (IWR) system at these 
visits will tell the site which treatment bottles have been assigned to the patient. 
In the event of loss of study medication, new medication will be provided by the IWR system, 
when appropriately requested by the site and/or the sponsor or designee. 
Study treatments for the double-blind treatment phase are either: 
 
Treatment A: 2  TNX-102 SL 2.8 mg tablets (“TNX-102 SL”) to be taken sublingually 
once daily at bedtime. 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 38 of 84 
 
Treatment B: 2  placebo tablets (“placebo”) to be taken sublingually once daily at bedtime. 
9.4. 
Release of Clinical Study Supplies to the Investigator 
Tonix or Tonix’s designee’s standard operating procedures for releasing clinical trial supplies to 
the site will be followed. 
9.5. 
Study Drug Accountability and Reconciliation 
All patients will be expected to bring their bottles of study medication with them to all study 
visits.  At each study visit, the site staff will inspect the medication bottles, and perform a count 
of the tablets remaining in the bottles and document this in the patient’s record.  An assessment 
of medication adherence should be done by the study staff to ensure that the patient understands 
all dosing instructions and is taking the medication as prescribed.  Patients will be asked for an 
explanation if the count of returned study drug tablets indicates a discrepancy between the 
expected number of tablets dosed and the number returned in the bottles.  If it is found that the 
patient is not taking the study medication as expected, the patient will be re-counseled with 
instructions, and this should be noted in the patients’ records.  A deviation should be recorded on 
any patient who is less than 70% compliant with dosing between visits. 
If the patient fails to return any of the unused study drug as expected, the patient should be 
questioned regarding the reason for the lower than expected tablet number and about potential 
misuse, abuse or diversion.  If more than 8 tablets cannot be accounted for at any of the visits 
where drug is returned (Week 4, 8 and 12), the investigator will be asked to evaluate the 
situation, and a written summary of this evaluation should be added to the source and entered 
onto the case report form (CRF).  Situations where replacement drug is requested, or when more 
than 8 tablets cannot be accounted for, should be recorded as deviations.   
All study medication, including partial and empty bottles, must be maintained at the study site 
until Tonix or its designee verifies drug accountability and provides instruction for destruction or 
the return of the investigational product to the Sponsor’s drug distribution depot. 
Tonix or their designee will perform drug accountability which entails reconciliation between the 
amount of drug shipped to the study site, study drug assigned and dispensed to the patient 
(including returned unused assigned study drug), and study supplies that were never dispensed 
and/or assigned to patients. 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 39 of 84 
 
10. 
STUDY VISITS AND PROCEDURES 
The overall and detailed schedule for study procedures and visits is provided in Appendix 1. 
10.1. 
Visit 1 (Screening: Day -21 to -7) 
10.1.1. 
Informed Consent 
Before the potential patient has undergone any study-related screening procedures, including any 
downward titration or withdrawal of medications, the nature of the study and the potential risks 
associated with it will be explained to the patient, and the patient will be given an opportunity to 
ask questions to his or her satisfaction.  After all questions are answered, but before proceeding 
further, the patient must read and sign a written informed consent form.  This signed informed 
consent form will be retained in the Investigator’s study file, and the date the patient signed the 
form will be entered into the Case Report Form (CRF).  The patient will be provided with a copy 
of his or her signed and dated informed consent form.  The patient will be required to sign all 
updated informed consents. 
Separate written, signed informed consent must be obtained if the patient is to participate in the 
optional pharmacogenomic assessment.   
10.1.2. 
Screening Overview 
Screening Visit 1 will start a variable length screening period.  The length of the screening 
period is to be no shorter than 7 days, but may be as long as 21 days in order to accommodate 
medication taper and discontinuation or other study requirements. 
If the patient is eligible to continue in the study, and does not need to discontinue any excluded 
medication, the patient may be scheduled to return for Visit 2 (Randomization) in 7 (or more) 
days, assuming all screening evaluations have been completed, including confirmation of 
acceptable laboratory and ECG results.  If the patient needs to undergo taper and discontinuation 
of excluded medication, the Investigator will generate a written down titration schedule for the 
patient and will schedule Visit 2 such that the date of Visit 2 is at least 1 week after the date of 
the final dose of any excluded medication.  If additional clinic visits are deemed necessary by the 
investigator for clinical monitoring of the patient before scheduling Visit 2, such visits will be 
recorded as unscheduled visits. 
10.1.3. 
Patient Numbering 
All screened patients will be assigned a unique concatenated 6-digit site-patient number (e.g., 
202-012) by the IWR system.  A screening log or system documenting the following information 
will be recorded and maintained, and will include the patient’s initials, screening number, 
whether the patient was ultimately randomized or not, and if not randomized, the reason the 
patient was excluded/screen-failed. 
10.1.4. 
Screening and Assessments/Procedures 
The following screening assessments/procedures will be completed in the following general 
order: 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 40 of 84 
 
• Obtain written informed consent to participate 
• Obtain demographics, including alcohol, nicotine/tobacco (smoking and/or chewing), and 
marijuana use 
• Obtain medical history  
• Obtain prior and current medication history, including all prior PTSD therapies and other 
treatments for psychiatric indications  
• Obtain psychiatric history  
o Mini International Neuropsychiatric Interview (M.I.N.I. 7.0.2) 
o McLean Screening Instrument for Borderline Personality Disorder (MSI-BPD) 
• Administer PTSD Rating Scales: 
o Life Events Checklist (LEC-5) 
o Criterion A – Assessment Form (CA-AF) 
o Clinician Administered PTSD Scale (CAPS-5) (Since Last Month version)  
• Perform physical examination, including visual inspection of the oral cavity (including 
floor of mouth/sublingual area)  
• Obtain vital signs, height, weight and BMI 
• Draw samples for clinical laboratory tests for: 
o Chemistry, hematology, HIV and TSH, with free thyroxine also performed if TSH 
is outside the upper or lower limits of normal  
o Urine Drug Screen (central laboratory) 
o Serum pregnancy test (for women of child-bearing potential) 
• Conduct 12-lead electrocardiogram  
• Administer Depression/Suicidality Scales 
o Montgomery-Åsberg Depression Rating Scale (MADRS) 
o Columbia Suicide Severity Rating Scale (C-SSRS, Baseline/Screening Version,)  
• Review inclusion/exclusion criteria 
Only those patients meeting all of the inclusion and none of the exclusion criteria will be eligible 
to continue.  NOTE:  Final determination of eligibility based on clinical laboratory tests will be 
made when results have been returned. 
Sites will be asked to complete and submit to the Tonix medical monitoring team key screening 
information.  This information will be reviewed by the Tonix medical monitoring team to help 
ensure the selection of well-qualified patients.  The specific requirements and timelines 
associated with this pre-randomization review process will be outlined in a separate document. 
Once eligibility has been confirmed and authorization for randomization granted by a Tonix 
medical monitor, eligible patients will return to the clinic for Visit 2. 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 41 of 84 
 
There is no requirement for Follow-Up visits for patients who are screen failures.  Patients who 
fail to qualify should have their medication adjusted, as appropriate, per the judgment of the 
Investigator and be released from the clinic.  There will be no requirement to enter data into the 
electronic case report form (eCRF) for patients who are not randomized. 
10.2. 
Visit 2 (Baseline: Day 1) 
Visit 2 should be scheduled 7 to 21 days after Visit 1.  Study procedures will be completed 
(including qualifying baseline assessments for the C-SSRS and CAPS-5).  If the patient meets all 
randomization criteria, the patient will be randomized via the IWR system to receive double-
blind study medication. 
10.2.1. 
Pre-Randomization Assessments 
The following assessments must be completed at Visit 2 to confirm that the patient is eligible for 
randomization.  Upon arrival at the clinic, the following assessments should be done, in the 
following general order: 
• Assess occurrence of adverse events 
• Update medical history (with changes since screening noted) 
• Assess changes in medication history and concomitant medications 
• Obtain vital signs and weight 
• Administer CAPS-5 - “Symptom Severity Version”, using 1-week recall 
• Conduct urine drug screen (urine dipstick, only as necessary, if select Visit 1 tests were 
positive for excluded medications that required discontinuation prior to randomization) 
• Conduct urine pregnancy test (for women of child-bearing potential)  
• Perform visual examination of the oral cavity  
• Have the patient complete the following outcome scales (in order): 
o SDS 
o PROMIS scale for sleep disturbance 
o CSFQ-14 
• Administer the MADRS  
• Administer the C-SSRS- Since Last Visit Version  
• Physician to assess CGI-S (needs to be completed once all other assessments are 
available for investigator to review) 
10.2.2. 
Randomization Criteria 
Once all pre-randomization assessments have been completed, only those patients who meet all 
of the following randomization criteria will be eligible to continue: 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 42 of 84 
 
1. Patient continues to meet all inclusion and exclusion criteria, including urine and blood 
test results, and 
2. Visit 2 total CAPS-5 score ≥ 33 (“Symptom Severity” version using 1-week recall), and 
3. No active suicidal intent or plan, or suicidal behavior, based on Investigator’s judgment, 
and Visit 2 C-SSRS responses (e.g., no C-SSRS Type 4-5 ideation or suicidal behavior 
since Visit 1) and/or a score of > 4 on Item 10 of the Visit 2 MADRS. 
If the patient does not satisfy these randomization criteria, the patient has failed to qualify for 
this study and should be considered a screen failure, with the reason documented.  With Medical 
Monitor approval, if the patient is otherwise considered a qualified and compliant patient, Visit 2 
may be delayed to accommodate situations in which extenuating or short-term circumstances do 
not warrant screen failure. 
If the patient does satisfy these randomization criteria, then continue with the following: 
• Randomize the patient via IWRS Randomization System 
• Dispense 4-week supply (two bottles) of double-blind study medication 
• Review patient instructions regarding study drug dosing (Section 9.2) 
• Schedule next study visit 
10.3. 
Visit 3 (Telephone Visit: Day 14) 
Visit 3 will be done as a telephone call to the patient and should be conducted after 2 weeks of 
treatment, on Day 14 ± 3 days. 
The following steps should be completed: 
• Assess changes in concomitant medications 
• Assess study drug compliance based on patient verbal report 
• Assess occurrence of adverse events, including any oral adverse events and whether an 
unscheduled visit is indicated for an examination of the oral cavity 
• Review patient instructions regarding drug dosing.  
• Administer the ‘Since Last Visit’ C-SSRS 
After all of the items have been reviewed with the patient, the patient should be given an 
appointment to return to the clinic for Visit 4, and be re-instructed, as necessary, on dosing 
instructions, and reminded to bring study medication back to the clinic at their next visit. 
10.4. 
Visit 4 and 5 (Weeks 4 through 8) 
Visits 4 and 5 are similar study visits that are scheduled to be conducted after 4 and 8 weeks of 
treatment, respectively.  Visit 4 should occur on Day 28 ± 5 days and Visit 5 should occur on 
Day 56 ± 5 days. 
The following assessments and procedures are scheduled for these visits in the following general 
order: 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 43 of 84 
 
• Collect study drug and assess compliance 
• Assess occurrence of adverse events 
• Update concomitant medications 
• Obtain vital signs and weight 
• Administer CAPS-5-“Symptom Severity Version” using 1-week recall 
• Conduct urine pregnancy test (for women of child-bearing potential) 
• Have the patient complete the following outcome scales (in order): 
o SDS 
o PROMIS scale for sleep disturbance 
o PGIC 
• Administer the MADRS  
• Administer C-SSRS - Since Last Visit Version 
• Physician to assess CGI-S and CGI-I (needs to be completed once all other assessments 
are available for investigator to review) 
• Dispense new bottles of double-blind study medication as assigned by IWRS 
After all of the assessments at each visit have been completed, the patient should be given an 
appointment to return to the clinic for the next scheduled visit, and be re-instructed, as necessary, 
on dosing instructions, and reminded to bring study medication back to the clinic at their next 
visit. 
10.5. 
Visit 6 (Week 12) 
Visit 6 should occur after 12 weeks of double-blind study drug treatment, scheduled at Day 84 -5 
/ +7 days.  The following assessments and procedures are to be completed in the following 
general order: 
• 
Collect study drug and assess compliance 
• 
Assess occurrence of adverse events 
• 
Update concomitant medications  
• 
Obtain vital signs and weight 
• 
Administer CAPS-5-“Symptom Severity Version” using 1-week recall 
• 
Conduct urine pregnancy test (for women of child-baring potential). Serum pregnancy 
test may be done at Investigator’s discretion.  
• 
Draw samples for clinical laboratory tests for: 
− Chemistry and hematology 
• 
Perform visual examination of oral cavity  

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 44 of 84 
 
• 
Have the patient complete the following outcome scales (in order): 
o SDS 
o PROMIS scale for sleep disturbance 
o PGIC 
o CSFQ-14 
• 
Administer the MADRS  
• 
Administer C-SSRS-Since Last Visit Version 
• 
Physician to assess CGI-S and CGI-I (needs to be completed once all other assessments 
are available for investigator to review) 
10.5.1. 
Early Termination (ET) 
In accordance with the Declaration of Helsinki, patients have the right to withdraw from the 
study at any time for any reason, and they will be advised of this right.  The investigator and 
Tonix also have the right to remove patients from the study.  Specific reasons for removal of a 
patient from the study could include, but are not limited to: 
• 
An adverse event (AE) 
• 
An illness that, in the judgment of the investigator or Tonix, might invalidate the study 
results or place the patient at risk 
• 
The request of the patient, investigator, or Tonix, whether for administrative or other 
reasons 
• 
Pregnancy 
This study will attempt to obtain as complete information as possible on all participating 
patients.  An effort must be made to contact the medical monitor prior to any patient’s early 
termination.  Each reason for early termination will be adjudicated.  Patients who wish to 
terminate their participation in the study should be instructed to come to the clinic for an Early 
Termination Visit.  The purpose of the Early Termination visit is to obtain critical information 
about the patient’s participation, and should be scheduled preferably before there has been a 
substantial lapse in study medication usage.  However, even if there has been a medication lapse, 
the patient should be encouraged to return to the clinic for this visit, and should be instructed to 
return all study medication.  NOTE:  These visit procedures are not intended for patients who fail 
to qualify for randomization or for any other reason withdraw from the study prior to receipt of a 
dose of double-blind study drug. 
If the patient withdraws prior to the Week 2 (Visit 3) visit window (before Day 11), the 
following assessments and procedures are to be completed at this visit in the following general 
order: 
• 
Document reason for early termination.  The investigator should carefully assess the role 
of adverse events and/or lack of efficacy when determining the most accurate reason 
for the patient’s early termination.   

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 45 of 84 
 
• 
Collect study drug and assess compliance 
• 
Assess occurrence of adverse events 
• 
Update concomitant medications 
• 
Obtain vital signs and weight 
• 
Conduct urine pregnancy test (for women of child-bearing potential). Serum pregnancy 
test may be done at Investigator’s discretion. 
• 
Draw samples for clinical laboratory tests for: 
o Chemistry and hematology 
• 
Perform visual examination of oral cavity 
• 
Have the patient complete the following outcome scales (in order): 
o CSFQ-14 
• 
Administer the MADRS  
• 
Administer C-SSRS – Since Last Visit Version 
If the patient withdraws after the Week 2 (Visit 3) visit window (on or after Day 11), the 
following assessments and procedures are to be completed at this visit in the following general 
order: 
• 
Document reason for early termination. The investigator should carefully assess the role 
of adverse events and/or lack of efficacy when determining the most accurate reason for 
the patient’s early termination.   
• 
Collect study drug and assess compliance 
• 
Assess occurrence of adverse events 
• 
Update concomitant medications 
• 
Obtain vital signs and weight 
• 
Administer the CAPS-5-“Symptom Severity Version” using 1-week recall 
• 
Draw samples for clinical laboratory tests for: 
o Chemistry and hematology 
o Serum pregnancy test (for women of child-bearing potential) 
• 
Conduct visual examination of oral cavity 
• 
Have the patient complete the following outcome scales (in order): 
o SDS 
o PROMIS scale for sleep disturbance 
o PGIC 
o CSFQ-14 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 46 of 84 
 
• 
Administer the MADRS  
• 
Administer C-SSRS- Since Last Visit Version 
• 
Physician to assess CGI-S and CGI-I (needs to be completed once all other assessments 
are available for investigator to review) 
Once these assessments have been completed, the patient may be discharged from the study, 
provided that there is no need for additional follow-up to continue to monitor an adverse event or 
other condition.  
10.5.2. 
Unscheduled Visits 
Patients may need to be seen at other times than the scheduled study visits for additional safety 
assessments or to follow-up, as medically necessary, on clinical laboratory results, physical 
examination, or other findings.  If an additional study visit is warranted, or occurs, the date and 
nature of the visit will be documented in the CRF and in the source documents. 
Patients who call to report an oral AE that is a lesion of some form should be brought back to the 
clinic for an unscheduled oral exam if deemed appropriate. In the case in which the AE is solely 
sensory in nature (such as oral hypoaesthesia) and the patient reports there is no discernable 
associated lesion, an unscheduled oral exam is not required but may be arranged if the 
investigator determines it to be clinically appropriate. 
10.6. 
Pharmacogenomic Assessment 
Patients should be offered the opportunity to participate in the pharmacogenomic assessment.  
The blood draw for this assessment can be done at any in-clinic visit post-Screening. It should be 
obtained after the patient has reviewed and signed the separate pharmacogenomic testing 
informed consent form, irrespective of the visit at which the main study consent is signed.    
 
 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 47 of 84 
 
11. 
STUDY ASSESSMENTS 
11.1. 
Screening Assessments 
11.1.1. 
Psychiatric and Medical History 
A psychiatric interview using the Mini International Neuropsychiatric Interview (M.I.N.I.-
Version 7.0.2)(Sheehan et al, 1998), a self-assessed McLean Screening Instrument for Borderline 
Personality Disorder (MSI-BPD) and a comprehensive medical history will be obtained at 
screening in order to determine whether the patient is eligible for enrollment. 
While patients with mild traumatic brain injury (TBI) are eligible to participate in the study, 
moderate and severe TBI are excluded.  Mild TBI (or concussion) is one of the most common 
forms of combat-related injury.  Based on self-report data, approximately 15% of troops engaged 
in active combat in Afghanistan and Iraq may have suffered a mild TBI (Hoge et al., 2008).  In 
the non-military population, common traumatic brain injuries result from falls, motor vehicle 
accidents, assaults, and sports injuries. A history of TBI is defined as any traumatically induced 
structural injury and/or physiological disruption of brain function as a result of an external force 
that is indicated by new onset or worsening of at least one of the following clinical signs, 
immediately following the event: 
1. Any period of loss of or a decreased level of consciousness; 
2. Any loss of memory for events immediately before or after the injury; 
3. Any alteration in mental state at the time of the injury (e.g., confusion, disorientation, 
slowed thinking); 
4. Neurological deficits (e.g., weakness, balance disturbance, praxis, paresis/plegia, change 
in vision, other sensory alterations, aphasia) that may or may not be transient;  
5. Intracranial lesion. 
Although severity of TBI depends in part on patient assessment in the days after a traumatic head 
injury, for the purposes of this protocol, mild TBI is defined as: 
1. Normal structural brain imaging findings 
2. Loss of consciousness not greater than 30 minutes after injury 
3. Alteration of consciousness not greater than 24 hours after injury 
4. Posttraumatic amnesia not more than 24 hours after injury 
5. No ongoing neurological deficits (Note: tinnitus, headaches, or sleep disturbances that 
appeared to result from the head trauma would not be considered as ongoing neurological 
deficits and therefore should not be interpreted as meaning the person has a greater 
severity than mild TBI.) 
Each incidence of traumatic brain injury in a patient’s lifetime history should be assessed using 
these five rule outs for greater than mild TBI, which is exclusionary for the protocol. 
In addition, the past medication history will be reviewed.  Any psychiatric medication or PTSD 
therapies utilized during the patient’s lifetime should be collected.  Responses from the M.I.N.I. 
and MSI-BPD will serve to document the presence or suspicion of other psychiatric conditions.  
The diagnosis and severity of PTSD will be based on the CAPS-5 (Section 11.2.1). 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 48 of 84 
 
11.2. 
Efficacy Assessments 
The primary efficacy endpoint and many of the secondary and exploratory efficacy endpoints in 
this study are derived from clinician-administered assessments which must be administered by 
qualified and trained individuals at each clinical site.  Study specific training will be required 
before staff is allowed to administer these scales.  In an attempt to minimize variability in 
responses of a given patient over time, it is important that the same rater administer the scales to 
a given patient throughout the study unless absolutely unavoidable due to the rater’s absence 
from the clinic.  It is also important that the assessments, including those that are patient-
completed, be conducted in the specified order, according to specific instructions, and in a 
setting where the patient has minimal distractions, appropriate privacy and sufficient time to 
complete them. 
11.2.1. 
Clinician-Administered PTSD Scale (CAPS-5) 
The CAPS-5 is an updated and validated version of a semi-structured interview that has been 
designed to assess the essential features of PTSD as defined by the DSM-5 (Weathers et al, 
2013).  The CAPS-5 affords the clinician flexibility to inquire about symptoms and diagnostic 
status over different time frames, such as past week, past month, and/or worst month for lifetime.  
For this study, a “Diagnostic” version of the CAPS-5 (lifetime and past month recall) will be 
utilized at the Screening visit to confirm the diagnosis of PTSD and determine eligibility based 
on symptom severity.  A “Symptom Severity” version of the CAPS-5 (past week recall) will be 
completed by clinician at all other time points (Baseline [Visit 2] and after 4, 8 and 12, weeks of 
treatment [Visits 4, 5 and 6]).  A CAPS-5 total score of 29 or above at Screening (“Diagnostic” 
version) and 33 and above at Baseline (“Symptom Severity” version) is requisite for eligibility. 
In addition to the total symptom score, the CAPS-5 affords the opportunity to examine clusters 
of symptoms, including Criterion B (intrusion symptoms), Criterion C (persistent avoidance), 
Criterion D (negative cognitions and mood), and Criterion E (arousal and reactivity), all of which 
will be secondary efficacy endpoints. 
The CAPS-5 interview contains the following components: 
• Life Events Checklist for DSM-5 (LEC-5):  Completed by the patient at Screening Visit 1 
only) and reviewed by the rater of the CAPS-5 interview at the start of the interview. 
• PTSD Symptoms 
o Criterion A: the rater will review the patient-completed LEC-5 and then inquire 
into the qualifying index trauma (Criterion A) utilizing the study-specific 
Criterion A - Assessment Form (CA-AF) (Visit 1 only) 
o Criterion B: Items 1-5 
o Criterion C: Items 6-7 
o Criterion D: Items 8-14 
o Criterion E:  Items 15-20 
o Criterion F: Items 21-22 
o Criterion G: Items 23-25 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 49 of 84 
 
o Global ratings: Items 26-28 
o Dissociative symptoms: Items 29-30 
Further instruction on when to complete each component will be provided in the study specific 
versions of the CAPS-5 forms. 
The LEC-5, which documents the patient’s lifetime traumatic experiences, will be completed by 
the patient at Screening Visit 1 before the clinician administered CAPS-5 (Weathers et al, 2013).  
The CAPS-5 rater will be responsible for reviewing the answers on this form with the patient as 
part of the completion of the CAPS-5 Criterion A - Assessment Form (CA-AF)  in order to 
determine if the traumatic experience qualifies the patient for inclusion in the study.  NOTE:  If 
worst month lifetime PTSD symptoms resulted from earlier trauma(s), such as trauma(s) before 
age 18 or trauma(s) occurring >9 years prior to screening, the prospective patient should be 
excluded from participation. 
At Screening, the total CAPS-5 score (Diagnostic version with 1-month recall) must be ≥ 29 and 
must meet the other diagnostic criteria specified in Inclusion Criterion 2 (Section 8.2) in order 
for the patient to continue.  At Baseline (Visit 2), the total CAPS-5 score (past week recall) must 
be ≥ 33. 
The CAPS-5 interview must be completed by a qualified and trained rater.  This rater should be 
kept consistent for a given patient throughout the study.  If circumstances require non-conformity 
with the single rater approach for any patient, this should be documented.  Additional 
information regarding the conduct, rating, and scoring of the CAPS-5 instrument as well as the 
requirements for rater training will be provided separately. 
11.2.2. 
Montgomery-Åsberg Depression Rating Scale (MADRS)  
The MADRS is a validated, 10-item, clinician-administered depression scale that has been used 
in clinical research since 1979 (Montgomery & Åsberg, 1979).  The MADRS scale will be 
completed at Screening (Visit 1), Baseline (Visit 2) and after 4, 8 and 12 weeks of treatment 
(Visits 4, 5 and 6, respectively).  The 10 items measure the core symptoms and cognitive features 
of clinical depression.  This scale has historically been used in drug-treatment trials due to its 
particular sensitivity to detect treatment effects.  Since there is a comparative lack of emphasis 
on somatic symptoms, the scale is useful for the assessment of depression in subjects with 
physical illness (as may be the case in subjects with PTSD). 
Patients with a Screening MADRS score of > 26 may be randomized upon Medical Monitor 
approval, based on a review of all Screening rating scales and the patient’s psychiatric/medical 
history. 
11.2.3. 
Clinical Global Impression of Severity (CGI-S) 
The CGI-S will be completed by an Investigator to evaluate the patient’s severity at the time of 
the assessment. The CGI-S, status since initiation of treatment, is a key secondary efficacy 
endpoint in this study. The CGI-S should be completed toward the end of each in-clinic study 
visit, except Screening, once all of the assessments are available for the investigator’s review. 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 50 of 84 
 
11.2.3.1. CGI-S Assessments  
An Investigator will complete the CGI-S assessment at Baseline, Week 4, 8 and 12 (Visits 2, 4, 5 
and 6, respectively) in order to assess the overall patient severity status, and answer the 
following question: 
Considering your total clinical experience with this particular population, how mentally ill is the 
patient at this time? 
 
0 = Not assessed 
 
1 = Normal, not ill at all 
 
2 = Borderline mentally ill 
 
3 = Mildly ill 
 
4 = Moderately ill 
 
5 = Markedly ill 
 
6 = Severely ill 
 
7 = Among the most extremely ill patients 
 
11.2.4. 
Clinical Global Impression of Improvement (CGI-I) 
The CGI-I will be completed by an Investigator to evaluate the patient’s status since initiation of 
treatment. The CGI-I should be completed toward the end of each in-clinic post-Baseline study 
visit once all of the assessments are available for the investigator’s review.   
11.2.4.1. CGI-I Assessments  
Once the patient has been randomized, an Investigator will complete the CGI-I assessment after 
4, 8 and 12 weeks of treatment (Visits 4, 5 and 6 respectively) in order to assess the overall 
change in the patient’s status since Baseline and answer the following question: 
Since the initiation of treatment at Visit 2, the patient is: 
1 = Very much improved 
2 = Much improved 
3 = Minimally improved 
4 = No change 
5 = Minimally worse 
6 = Much worse 
7 = Very much worse 
11.2.5. 
Patient Global Impression of Change (PGIC) 
The PGIC is a validated, self-report instrument to gauge the patient’s assessment of change in 
condition.  This form will be completed by the patient after 4, 8 and 12 weeks of treatment 
(Visits 4, 5 and 6 respectively).  The patient will answer a single question: 
Since the initiation of study medication, overall, my PTSD symptoms are: 
1 = Very much improved 
2 = Much improved 
3 = Minimally improved 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 51 of 84 
 
4 = No change 
5 = Minimally worse 
6 = Much worse 
7 = Very much worse 
11.2.6. 
PROMIS Sleep (short form) Scale 
PROMIS refers to the Patient-Reported Outcome Measurement Information System 
(www.nihpromis.org), an NIH-funded initiative to develop instruments to be used across chronic 
conditions. 
The PROMIS Sleep scale (short form 8a) will be assessed at Baseline (Visit 2) and after 4, 8 and 
12 weeks of treatment (Visits 4, 5 and 6 respectively). 
11.2.7. 
Sheehan Disability Scale (SDS) 
The SDS scale is a self-report questionnaire that was designed to assess the patient’s view of the 
degree to which symptoms have disrupted work, social life/ leisure activities, and family life/ 
home responsibilities during the past 1 week (Sheehan & Sheehan, 2008).  In addition, the SDS 
asks the patient to provide the number of days or work lost as well as unproductive days in the 
past week.  The SDS scale will be completed by the patient at Baseline (Visit 2), and after 4, 8 
and 12 weeks of treatment (Visits 4, 5 and 6 respectively).  
11.3. 
Safety Parameters 
Safety will be assessed by evaluation of adverse events, responses on the C-SSRS and MADRS, 
clinical laboratory tests, vital signs, weight, and patient ratings of sexual function assessed by the 
CSFQ-14. 
11.3.1. 
Adverse Events (AEs) 
Patients will be monitored for AEs throughout the study from the time that the patient signs an 
informed consent and onward.  AEs that are spontaneously reported, elicited or observed are to 
be recorded on the CRF with the date, time of onset, date and time of resolution, severity, 
seriousness, causality (relationship to study medication), actions required, and outcome. 
To elicit AEs, non-leading, simple questions with minimal connotations should be used as the 
initial questions at all evaluation points during the study.  Examples of these questions can be: 
• 
How have you felt since your last visit? 
• 
Have you had any health problems since your last visit? 
If an AE occurs, the investigator will institute support and/or treatment as deemed appropriate.  
If a non-serious AE is unresolved on the last day of the study, an effort should be made to follow 
up until the AE is resolved or stabilized, the patient is lost to follow-up, or there is some other 
resolution of the event. 
There are many symptoms associated with PTSD that can vary in intensity and frequency over 
time.  Only symptoms that significantly worsen or become more frequent, in the opinion of the 
patient and outside of their normal experience, should be reported as an adverse event. 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 52 of 84 
 
If a patient reports an oral cavity adverse event, the Investigator should examine the oral cavity 
to confirm the presence or absence of any irritation or other signs.  Additional details related to 
onset, duration, severity and reversibility of the oral cavity event will be documented 
(Section 11.3.5). 
Additional information regarding definition and reporting requirements for adverse events, 
serious adverse events, and pregnancies is provided in Section 11.3.1. 
11.3.2. 
Columbia-Suicide Severity Rating Scale (C-SSRS) 
The C-SSRS is a questionnaire developed by researchers at Columbia University to assess 
suicide risk and to track suicidal ideation and behavior during clinical trials.  This scale is 
intended to be used by individuals who have received training in its administration.  The 
questions contained in the Columbia-Suicide Severity Rating Scale are suggested probes.  
Ultimately, the determination of the presence of suicidal ideation or behavior depends on the 
judgment of the individual administering the scale. 
There are multiple versions of this questionnaire.  At Visit 1, the “Baseline/Screening” 
questionnaire will be administered and the recall periods will be “lifetime” and “within the past 6 
months” for suicidal ideation, and “within the past year” for suicidal behaviors.  Patients whose 
responses are indicative of suicidal ideation with intent and/or plan (e.g., Type 4-5 ideation) 
within the past 6 months or a history of prior suicidal behavior within the past year will be 
excluded from participation, with recommended referral for appropriate intervention. 
At all subsequent visits (Visit 2 through 6), the “Since Last Visit” questionnaire will be 
administered, and the recall period on this will be “since the last visit”.  Note that if there has 
been a significant change in responses indicative of increased suicide risk, appropriate 
intervention should be prescribed as described below. 
11.3.3. 
Safety Planning Intervention (SPI) 
The C-SSRS is completed at every visit in order to assess for changes in suicidality during the 
study.  As a screening and baseline entrance criterion, patients exhibiting Type 4 or 5 ideation in 
the past 6 months or a history of suicidal behavior in the past 12 months are not eligible for the 
study due to this risk and should be referred for appropriate emergency care.  If a patient scores a 
4 or 5 at a clinic visit following randomization, the patient should be withdrawn from the study 
and referred for appropriate emergency care.  If a patient scores a 4 or 5 at any clinic visit, it 
should be reported as a serious adverse event. 
If a patient scores a 2 or 3 on the suicidal ideation section of the C-SSRS at any visit (including 
the Screening visit), the investigator and patient should work together to implement a Safety 
Planning Intervention (SPI).  In addition, if a post-baseline score of 2 or 3 represents a significant 
change from the patient’s baseline status, it should be recorded as an adverse event. The 
recommended SPI for this study is the plan developed by Barbara Stanley, PhD and Gregory 
Brown, PhD which has been adopted by the U.S. Veteran’s Administration (VA) (Stanley & 
Brown, 2012).  The VA SPI is a brief clinical intervention aimed at mitigating suicide risk.  It 
consists of a written, prioritized list of coping strategies and sources of support that patients can 
use to alleviate a suicidal crisis.  Sites may use an internally-developed SPI if similar in scope 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 53 of 84 
 
and purpose to the VA SPI.  Additional information and training on the implementation of an 
SPI will be provided prior to initiation of the study. 
11.3.4. 
Physical Examination 
A complete physical examination will be performed at Screening Visit 1 only.  At a minimum, 
the physical examination will include the following components: HEENT (head, eyes, ears, nose, 
and throat), neck, chest and lungs, cardiovascular, abdomen, skin, and musculoskeletal.  The 
physical examination may exclude rectal, genitourinary, and breast examinations. 
11.3.5. 
Visual Examination of Oral Cavity 
A visual examination of the oral cavity should be done at Screening (Visit 1), Baseline (Visit 2) 
and after 12 weeks (Visit 6) of treatment and/or at Early Termination.  In addition to these 
regularly scheduled examinations, a visual inspection of the oral cavity (including the sublingual 
area) should be done any time a patient spontaneously reports an oral adverse event (other than 
transient sensory AEs such as tongue numbness, tingling or bitter taste) to confirm presence or 
absence of any irritation or other signs.  Additional details related to onset, duration, severity and 
reversibility of oral events will be documented in the CRF. 
11.3.6. 
Vital Signs, Height and Weight 
Vital signs (sitting blood pressure and heart rate, temperature, and weight) will be assessed at 
Screening (Visit 1), Baseline (Visit 2) and after 4, 8 and 12 weeks of treatment (Visits 4, 5 and 
6/Early Termination, respectively).  Height will be measured without shoes at Visit 1 only.  The 
BMI will be a derived variable, based on height and weight entries.  A BMI > 40 is an exclusion 
criterion. 
11.3.7. 
Electrocardiogram (ECG) 
A 12-lead ECG will be performed at Screening (Visit 1) and will be reviewed by the Investigator 
for the purpose of excluding from participation patients who have either a history of or current 
evidence of clinically significant cardiac disease (e.g., significant arrhythmias or heart block, 
heart failure, or myocardial infarction within the past 2 years) or a QTcF at Screening > 
450m/sec (males) or QTcF > 470m/sec (females). 
The ECG interpretation by the Investigator will be recorded in the CRF as normal, abnormal but 
clinically insignificant, or abnormal and clinically significant.  In addition, the standard ECG 
parameters including rhythm, heart rate, and intervals for PR (or PQ), QRS, and QTcF 
(Fridericia’s) corrections for heart rate will be recorded. 
If the Investigator has any concerns about the eligibility of a patient or wishes to confirm his/her 
assessment, the Investigator should consult with the medical monitor for this study. 
11.3.8. 
Clinical Laboratory Assessments 
The clinical laboratory evaluations to be performed in this trial are listed in Table 1.  Those 
marked as screening tests will be performed at screening only.  All other tests will be performed 
at Screening (Visit 1) and after 12 weeks of treatment (Visit 6), or Early Termination.  Clinical 
laboratory values may be repeated prior to randomization in order to confirm exclusionary levels 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 54 of 84 
 
for TSH, ALT and/or AST values.  If these values remain persistently elevated upon repeat, the 
patient is not eligible for randomization. 
With the exception of the urine pregnancy tests or the ad hoc urine drug test required at baseline 
for patients washing off excluded medications (e.g., opioids, benzodiazepines, amphetamines), 
all clinical laboratory evaluations will be analyzed via a central clinical laboratory, and 
information regarding appropriate sample volume, collection tubes, sample labeling and 
handling, and shipment will be provided in a study manual. 
A urine drug screen for drugs of abuse (including marijuana) will be collected at Screening 
Visit 1 and sent to the central laboratory for analysis.  If the patient has a positive drug screen at 
Visit 1 and/or Visit 2 for anything other than marijuana, and the results cannot be explained by 
use of current allowable prescription medications, the patient should be excluded from the study.  
If the urine drug screen is positive at Visit 1 and the results can be explained by the use of 
current prescription medications (e.g., opioids, , amphetamines) that will be discontinued during 
screening, the investigator must repeat the drug screen and obtain a negative result using an in-
clinic urine dipstick drug screen prior to randomization to confirm eligibility for the study. 
Patients with positive results for benzodiazepines at Screening will need to come back to the 
clinic for repeat centralized Urine Drug Screen following a minimum of one week off all 
benzodiazepines.  And since the results of the repeat UDS must be confirmed negative prior to 
randomization, the Baseline visit should take place no sooner than 7 days after the patient’s post-
washout urine drug screen.  
Each clinically significant abnormal laboratory value or other clinically meaningful abnormality 
should be followed until the abnormality resolves or until a decision is made that it is not likely 
to resolve.  If such abnormalities do not return to normal within a reasonable period, their 
etiology should be identified and Tonix or designee should be notified.  Treatment-emergent 
clinically significant abnormalities in laboratory values will be recorded as AEs. 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 55 of 84 
 
Table 1: 
Clinical Laboratory Assessments 
Clinical chemistry 
Hematology 
Alanine aminotransferase (ALT)a  
Hematocrit 
Alkaline phosphatase 
Hemoglobin 
Aspartate aminotransferase (AST)a  
MCH concentration (MCHC) 
Bilirubin (total) 
Mean corpuscular hemoglobin (MCH) 
Blood urea nitrogen (BUN) 
Mean corpuscular volume (MCV) 
Calcium 
Platelet count 
Chloride 
Red blood cell (RBC) count 
Cholesterol (total) 
WBC differential 
Creatine kinase (CK) 
Neutrophil count (absolute and %) 
Creatinine 
Lymphocyte count (absolute and %) 
Glucose 
Monocyte count (absolute and %) 
Phosphorus 
Eosinophil count (absolute and %) 
Potassium 
Basophil count (absolute and %) 
Protein (albumin and total) 
White blood cell (WBC) count 
Sodium 
 
Thyroid-stimulating hormone (TSH) c at 
screening 
Serum Pregnancy Test at Screeningb 
Free T4 only if TSH is outside of normal limits 
Urine Pregnancy Test (qualitative dipstick)b 
Human immunodeficiency virus types 1 and 2 
(HIV1 and HIV2) 
Urine Drug Screend 
Pharmacogenomic testing (optional; can be 
obtained at any visit post-Screening, 
including an early termination visit) 
 
a  Level greater than 3 times the upper limit of normal is an exclusion (if persistent upon repeat). 
b Pregnancy testing for females of child-bearing potential only.  A positive pregnancy test is exclusionary (Visit 1 or Visit 2) or mandates 
withdrawal from the study (all other visits). 
c TSH level greater than 1.5 times higher than the upper limit of normal is exclusionary at Visit 1. 
d Urine drug screening will be conducted on all patients at Screening and, if necessary, at Baseline in patients with a positive result for opioids, 
barbiturates, amphetamines or oxycodone at Screening and who otherwise qualify for the study.  For patients testing positive at the Screening 
visit for an excluded medication that will be discontinued during the screening interval, an in-clinic urine dipstick drug screen will be 
performed at the Baseline visit and must be negative in order for the patient to be eligible for randomization (this will primarily apply to  
opioids and amphetamines).  Patients with positive results for Benzodiazepines at Screening will need to come in to the clinic for a repeat 
centralized Urine Drug Screen following a one-week drug free interval, and the Baseline Visit may need to be delayed in order to ensure that 
the results from the repeat centralized UDS can be confirmed negative prior to randomization.   
11.3.9. 
Pharmacogenomics Testing 
For pharmacogenomic analysis, a single blood draw collected in two PAXgene DNA tubes will 
be obtained from each patient after they have provided separate written, signed informed consent 
for pharmacogenomic analysis.  The purpose of this testing is to allow exome sequencing and 
analysis for genetic variants related to treatment response to TNX-102 SL. It is presumed that 
unused sample will be stored up to fifteen years, and potentially utilized to develop a 
pharmacogenomic test for determining likelihood of treatment response to TNX-102 SL.  A 
decision not to participate in optional pharmacogenomic testing will not affect the patient’s 
eligibility for the main study. Patients have the right to stop participating at any time during the 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 56 of 84 
 
study or during the time of sample storage, and, if a patient decides to withdraw from the 
pharmacogenomics portion of this study, any remaining sample will be destroyed and not used 
for further research.  Data collected before a patient’s withdrawal from the pharmacogenomics 
portion of this study will remain in the research database. 
11.3.10. 
Assessment of Changes in Sexual Function: Changes in Sexual Functioning 
Questionnaire Short-Form (CSFQ-14) 
The Changes in Sexual Functioning Questionnaire Short-Form (CSFQ-14) (Keller et al. 2006) is 
validated scale with internal reliability designed to allow a patient to self-evaluate his or her 
sexual behaviors or problems in a number of areas.  The CSFQ-14 will be administered at 
Baseline (Visit 2) and Week 12/ET (Visit 6).  It yields a total score, three subscales 
corresponding to phases of the sexual response cycle (i.e. desire, arousal, orgasm), and five 
subscales corresponding to important dimensions of sexual functioning.  It is considered a useful 
scale for assessing sexual side effects of medications.  For all items, higher scores reflect higher 
sexual functioning.  For 12 of the 14 items, higher sexual functioning corresponds to greater 
frequency or enjoyment/pleasure (e.g. 1=never to 5 = every day).  For two items (item 10, 
assessing loss of interest after arousal for women and priapism for men, and item 14, assessing 
painful orgasm), higher sexual functioning corresponds to lower frequency (e.g. 1=every day to 
5=never). Items 10 and 14 are included in the total score but not in any scale score. 
 
12. 
DEFINITIONS, RECORDING, AND REPORTING OF ADVERSE 
EVENTS 
12.1. 
Definition of Adverse Events 
According to International Conference on Harmonization (ICH) guidance E2A, Clinical Safety 
Data Management: Definitions and Standards for Expedited Reporting, an adverse event (AE) is 
any untoward medical occurrence in a patient or clinical investigation patient administered a 
pharmaceutical product and which is not necessarily required to have a causal relationship with 
this treatment.  An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding, for example), symptom, or disease temporally associated with the 
use of a medicinal product, whether or not considered related to the medicinal product. 
A treatment-emergent AE (TEAE) is an AE that either commenced following initiation of study 
treatment or was present prior to study treatment but increased in frequency or severity following 
initiation of study treatment. 
12.2. 
Adverse Event Recording 
12.2.1. 
Coding the Adverse Event 
Standard medical terminology should be used in describing AEs.  MedDRA® will be used as the 
standard coding dictionary for AEs and in describing the patient’s medical history, and the 
World Health Organization (WHO) Drug Dictionary will be used to code concomitant 
medications.  Informal descriptions should be avoided. 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 57 of 84 
 
12.2.2. 
Severity of Adverse Event 
AEs should be graded as mild, moderate, or severe using the following definitions. 
• 
Mild: Awareness of signs or symptoms, but easily tolerated and of minor irritant type 
causing no loss of time from normal activities.  Symptoms do not require therapy or a 
medical evaluation; signs and symptoms are transient. 
• 
Moderate: Events introduce a low level of inconvenience or concern to the patient and 
may interfere with daily activities, but are usually improved by simple therapeutic 
measures; moderate experiences may cause some interference with functioning. 
• 
Severe: Events interrupt the patient’s normal daily activities and generally require 
systemic drug therapy or other treatment; they are usually incapacitating. 
To make sure there is no confusion or misunderstanding of the difference between the terms 
“serious “and “severe,” which are not synonymous, the following note of clarification is 
provided.  The term “severe” is often used to describe the intensity (severity) of a specific event 
(as in mild, moderate, or severe myocardial infarction); the event itself, however, maybe of 
relatively minor medical significance (such as severe headache).  This is not the same as 
“serious,” which is based on patient/event outcome or action criteria usually associated with 
events that pose a threat to a patient's life or functioning.  Seriousness (not severity) serves as a 
guide for defining regulatory reporting obligations. 
12.2.3. 
Relationship of Adverse Events to Study Drug 
The investigator will assess the potential relationship of the AE to study drug using the following 
descriptions. 
• 
Not Related: This category applies to an AE that is clearly not related to the 
investigational agent/procedure, beyond a reasonable doubt.  That is, another cause of the 
event is most plausible; and/or a clinically plausible temporal sequence is inconsistent 
with the onset of the event and the administration of study drug and/or a causal 
relationship is considered biologically implausible. 
• 
Unlikely Related: This category applies to an AE that could reasonably be considered 
caused by something else, and where there is no known or expected response pattern to 
the suspected study drug. 
• 
Possibly Related: This category applies to an AE that follows a reasonable temporal 
sequence from administration of the study drug and that follows a known or expected 
response pattern to the suspected study drug, but that could readily have been produced 
by a number of other factors. 
12.3. 
Serious Adverse Events (SAEs) and Serious Adverse Drug Reactions 
Any SAE that occurs at any time during the study, including a clinically significantly abnormal 
laboratory test result that is considered serious, must be reported to Tonix or its designee(s) so 
that Tonix may comply with regulatory obligations.  If the SAE is life-threatening or fatal, it 
must be reported to Tonix or its designee(s) immediately, by facsimile and telephone.  For these 
and all other SAEs, an SAE report form must be completed and sent by facsimile or email to 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 58 of 84 
 
Tonix or its designee(s) within 1 working day of the site’s initial awareness of the event.  These 
requirements apply equally to all patients, regardless of the study phase or the at-risk patient’s 
treatment assignment or dosage. 
A serious adverse event (experience) or reaction is any untoward medical occurrence that, at any 
dose: 
• Results in death, 
• Is life-threatening, 
• Requires in-patient hospitalization or prolongation of existing hospitalization, 
• Results in persistent or significant disability/incapacity, 
• Is a congenital anomaly/birth defect, or 
• Is an important medical event 
NOTE: The term “life-threatening” in the definition of “serious” refers to an event in which the 
patient was at risk of death at the time of the event.  It does not refer to an event that 
hypothetically might have caused death if it were more severe. 
Medical and scientific judgment should be exercised in deciding whether expedited reporting is 
appropriate in other situations, such as important medical events that may not be immediately 
life-threatening or result in death or hospitalization but may jeopardize the patient or may require 
intervention to prevent one of the other outcomes listed in the definition above.  These should 
also usually be considered serious.  Examples of such events are intensive treatment in an 
emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do 
not result in hospitalization, or development of drug dependency or drug abuse. 
A death occurring during the study, during the per-protocol follow-up period, or reported to the 
Investigator after study participation (no required post-study time limit) must be reported to 
Tonix or its designee(s) immediately, whether or not it is considered treatment-related.  Initial 
SAE reports must be followed by detailed descriptions.  These should include copies of hospital 
case records and other documents when requested.  Telephone and e-mail reports must be 
confirmed promptly either by facsimile or by email.  For reporting SAEs, one of Tonix’s 
designated Medical Monitors should be called. 
The Investigator or other study personnel must immediately inform the one of Tonix Medical 
Monitors by phone or email of any AE considered serious or otherwise significant, as described 
above.  In addition, a completed SAE report form must be submitted to 
 
 within 24 hours of initial awareness of the event. 
 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 59 of 84 
 
 
 
Contact information for the Medical Monitors is provided below: 
 
 
For questions pertaining to the reporting of SAEs or the completion of SAE documentation, 
site personnel should call 
 
The investigator, or the sponsor or designee in the case of a central Institutional Review Board 
(IRB), also must notify the EC/IRB of the occurrence of the SAE, in writing, as soon as is 
practicable and in accordance with local law.  A copy of this notification must be provided to 
Tonix or its designee. 
In the event of an SAE that meets the criteria for expedited reporting, an Investigational New 
Drug (IND) Safety Report will be prepared for submission to the FDA. 
12.4. 
Pregnancy 
The active pharmaceutical product in TNX-102 SL 2.8 mg tablets is cyclobenzaprine HCl, which 
is in Pregnancy Category B (See Appendix 3 for AMRIX® Package Insert).  All pregnancies 
occurring during the study (after exposure to study drug) or within 30 days after discontinuation 
of study drug must be followed until resolution (i.e., birth or voluntary or spontaneous 
termination of the pregnancy) and reported within 24 hours of the site’s awareness to Tonix 
and/or its designee.  Any patient found to be pregnant at any time during the study will be 
withdrawn from the study immediately.  Any pregnancy outcome that meets the criteria for an 
SAE will be reported as an SAE. 
13. 
STATISTICS 
A full description of the statistical analyses to be performed at study completion will be provided 
in a Statistical Analysis Plan (SAP) prior to unblinding. 
Baseline will be defined as those values recorded closest to, but prior to administration of the 
first dose of study drug. 
Unless otherwise noted, significance tests of treatment differences will be tested at the two-sided 
0.05 level. 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 60 of 84 
 
13.1. 
Populations for Analysis 
The following populations will be defined for use in analyzing the efficacy and safety data in the 
study (see SAP for more details): 
• Safety Population (SAFETY):  All patients who receive at least 1 dose of study drug. 
All safety analyses and demographic/baseline characterization will be performed 
using this population, analyzed as treated, using the highest dose they were issued at 
any visit. 
• Modified Intention-to-Treat Population (mITT):  All randomized patients who have at 
least a baseline and one post-baseline CAPS-5 assessment.  This is the primary 
population for efficacy analyses and patients will be analyzed based on their 
randomized treatment. See Section 10.5.1 for early termination assessments. 
13.2. 
Estimate of Sample Size 
The study is planned to enroll approximately 250 patients total in a 1:1 randomization, that is, 
125 patients in each of the TNX-102 SL 5.6 mg and placebo arms.  
 
 
 
13.3. 
Assessment of Demographic and Baseline Characteristics 
Demographic and baseline characteristics such as age, gender, race/ethnicity, height, weight, 
BMI, presence of current major depressive episode, family status, education, employment status, 
and smoking history will be summarized by treatment group (TNX-102 SL and placebo) and 
overall using descriptive statistics. 
Medical History will be coded using MedDRA and summarized by SOC and Preferred Term 
using frequency counts by treatment group. 
13.4. 
Efficacy Analysis 
13.4.1. 
Efficacy Endpoints 
Primary Efficacy Endpoint: 
The mean change from baseline (Visit 2) in the Total CAPS-5 score evaluated at Week 12. 
Secondary Efficacy Endpoints: The efficacy endpoints listed below are considered key 
secondary endpoints and will be tested in the following order. 
• Change from baseline to Week 12 in CGI-S score. 
• Change from baseline to Week 12 in the SDS total score. 
• Change from baseline to Week 12 in the PROMIS Sleep Disturbance total score. 
Other Secondary Efficacy Endpoints:  
• Change from baseline to Week 12 in the disruption of work/school activities assessed 
using the SDS. 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 61 of 84 
 
• Change from baseline to Week 12 in disruption of social life/ leisure activities 
assessed using the SDS. 
• Change from Baseline to Week 12 in the disruption of family life/home 
responsibilities assessed using the SDS. 
• Change from baseline to Week 12 in CAPS-5 Arousal and Reactivity (Criterion E) 
score. 
• Change from baseline to Week 12 in CAPS-5 Intrusion symptoms (Criterion B) 
score. 
• Change from baseline to Week 12 in CAPS-5 Negative Cognition and Mood 
(Criterion D) score. 
• Change from baseline to Week 12 in CAPS-5 Persistent Avoidance (Criterion C) 
score. 
• Change from baseline to Week 12 in CAPS-5 Sleep Disturbance (item E-6) score. 
• Change from baseline to Week 12 in CGI-I.  
• Change from Baseline to week 12 in mean PGIC score 
• Proportion of patients with a treatment response on the CGI-I defined as a CGI-I 
score of “much improved” or “very much improved” at Week 12. 
• Proportion of patients with a PGIC score of “much improved” or “very much 
improved” at Week 12.  
• Proportion of patients with a Total CAPS-5 score of 0 –10 (asymptomatic/few 
symptoms) at Week 12. 
• Proportion of patients with a Total CAPS-5 score of 0 -22 (asymptomatic or mild 
PTSD/subthreshold) at Week 12. 
• Proportion of patients with Response, defined as a ≥ 10-point improvement from 
baseline at Week 12 in Total CAPS-5 score. 
• Proportion of patients with Loss of Diagnosis, defined as Response AND no longer 
meeting DSM-5 symptom criteria in any one or more of the four clusters (B, C, D, E) 
at Week 12. 
• Proportion of patients in Remission, defined as Loss of Diagnosis AND Total CAPS-
5 score ≤ 10 at Week 12.   
• Proportion of patients achieving sustained Remission, defined as Loss of Diagnosis 
AND Total CAPS-5 score ≤ 10 after both 8 weeks AND 12 weeks of treatment. 
• Proportion of patients with a ≥ 30%reduction from baseline to Week 12 in total 
CAPS-5 score. 
• Proportion of patients with a ≥ 50% reduction from baseline at Week 12 in Total 
CAPS-5 score. 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 62 of 84 
 
• Change from baseline at Week 12 in MADRS score. 
• Change from baseline at Week 12 in CAPS-5 Reckless or Self-Destructive Behavior 
(item E-2) score.  
• Changes from baseline in patient-rated Changes in Sexual Functioning Questionnaire 
Short-Form (CSFQ-14) in males and in females, analyzed separately 
Exploratory Endpoints:  Any exploratory endpoints will be delineated in the SAP.   
13.4.2. 
Primary Efficacy Analysis 
The primary efficacy analysis will use a mixed model repeated measures (MMRM) approach to 
estimate mean change from baseline in the Total CAPS-5 score evaluated at the Week 12 visit in 
the TNX-102 SL 5.6 mg and placebo arms.  The model will include all patients in the mITT 
population, and the dependent variable will be the observed change from baseline in total CAPS-
5 score at each post-randomization in-clinic visit.  Covariates in the model will include the fixed 
categorical effects of treatment, site, sex, visit, and treatment by visit interaction, as well as the 
continuous fixed covariates of baseline score and baseline score by visit interaction.  Missing 
data will be imputed via multiple imputation (MI), and details regarding the MI approach will be 
described in the SAP.   
The primary analysis will be followed by several sensitivity analyses.  Further details on 
sensitivity analyses can be found in the SAP. 
13.4.3. 
Secondary Efficacy Analyses 
MMRM methodology will be utilized for the continuous secondary endpoints, and analyses will 
be based on the mITT population.  The dependent variable will be the observed change from 
baseline in the respective secondary endpoint at each post-randomization visit, with the 
exception of those measures that do not have a baseline.  Covariates in the model will include the 
fixed categorical effects of treatment, site, sex, visit and treatment by visit interaction (baseline 
score and baseline score by visit interaction will be included as appropriate).   
Binary data will be analyzed using a Cochran-Mantel-Haenszel (CMH) test controlling for the 
randomization stratification of sex, analyzed separately at each visit.  Patients with missing data 
will be analyzed as though they are non-responders. Odds ratios and corresponding 95% 
confidence intervals will be presented. 
To adjust for multiplicity and to control for overall type I error, a sequential test procedure will 
be applied to the key secondary efficacy endpoints.  If the primary analysis produces a result that 
is statistically significant, a nominal significance level will be used for comparing the secondary 
endpoints in an ordered fashion.  If the analysis for a secondary endpoint does not produce a 
statistically significant result, then the remaining secondary endpoint analyses will automatically 
be considered non-significant regardless of the p-value produced.  In the case of an early stop or 
increase in sample size, the same methodology/critical value used for the primary endpoint will 
be applied to the key secondary endpoints for the purposes of the sequential testing.  See the SAP 
for additional details. 
The testing order for the three key secondary endpoints is as follows: 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 63 of 84 
 
• Change from baseline in CGI-S score at Week 12. 
• Change from baseline in the SDS total score at Week 12. 
• Change from baseline in PROMIS SD score at Week 12. 
No other adjustments for multiplicity will be made and other p-values displayed in the output 
will be considered for descriptive summary purposes only and will not be used for formal 
inference.  Full details regarding the statistical analyses for the listed endpoints will be provided 
in the SAP. 
13.4.4. 
Exploratory Analyses 
Exploratory efficacy analyses will be based on the mITT population.  Details on exploratory 
efficacy analyses can be found in the SAP. 
13.5. 
Safety Analyses 
Safety will be assessed by: 
• Adverse events and serious AEs throughout the entire duration of the study, including 
assessment of AEs involving the oral cavity 
• Changes from baseline in clinical laboratory test results 
• Changes from baseline in vital signs and weight 
• Changes from baseline indicative of increased suicidal ideation or behavior as 
assessed by the C-SSRS 
• Changes from baseline in MADRS scores 
• Changes from baseline in patient-rated sexual function as assessed by the CSFQ-14 in 
males and in females, described separately 
 
Adverse events will be coded using the latest version of MedDRA and will be summarized 
overall and by preferred term and system organ class.  Adverse events will also be summarized 
by severity and relationship to study drug.  Serious AEs and AEs leading to discontinuation of 
study drug will also be summarized.  Actual values and changes from Baseline for clinical 
laboratory test results, MADRS scores, CSFQ-14 scores, and vital sign measurements will be 
summarized at endpoint using descriptive statistics (n, mean, SD, median, minimum, and 
maximum). 
The number of patients with suicidal behaviors, ideations and acts based on the C-SSRS will be 
tabulated by treatment group and listed. 
13.6. 
Interim Analyses 
An interim analysis will be performed once approximately 50% of the planned patients have 
enrolled and those patients have either completed or discontinued the study.  The purpose of the 
interim will be to potentially increase the sample size to maintain statistical power conditioned 
on the results of the first 50% of patients; or stop the study for futility if the conditional power is 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 64 of 84 
 
sufficiently low.  The study team will only be informed of the recommendation to maintain the 
original sample size, increase the sample size (by a fixed, pre-specified amount) or discontinue 
the study (at which point unblinding would occur).    
For the primary and key secondary outcomes, the results from before and after the interim will 
be combined with Cui, Hung, Wang (CHW) methodology (Cui, 1999).  Full details of the 
interim analysis procedure and steps to maintain treatment blinding of the study team will be 
described in the SAP and the IDMC Charter and finalized prior to execution of the interim 
analysis. 
14. 
PROCEDURES FOR MODIFYING THE PROTOCOL OR 
TERMINATING THE STUDY 
14.1. 
Protocol Modifications and Deviations 
The investigator will make all reasonable efforts to comply with the written protocol and 
protocol amendments.  All protocol modifications must be reviewed and approved by the 
appropriate EC/IRB before the revised protocol can be implemented.  Emergency revisions that 
eliminate an apparent hazard to patients do not require preapproval by the EC/IRB.  However, 
the EC/IRB must be notified, in writing, as soon as possible after the modification has been 
made.  A copy of this communication must be forwarded to Tonix. 
14.2. 
Study Termination 
The study may be prematurely terminated at any time at the discretion of Tonix, its designee, or 
the principal investigator.  Should premature termination be considered necessary, written 
notification documenting the reason for study termination will be provided, and specific 
procedures for termination will be arranged.  Circumstances that may warrant premature study 
termination include, but are not limited to, the following. 
• 
Determination of unexpected, significant, or unacceptable risk to patients 
• 
Failure to enter patients at an acceptable rate 
• 
Insufficient adherence to the requirements of the protocol 
• 
Insufficient provision of complete and evaluable data 
• 
Plans to modify, suspend, or discontinue development of the study drug 
In the event that the study is terminated prematurely, all study materials must be returned to 
Tonix or its designee. 
15. 
ETHICAL CONSIDERATIONS 
15.1. 
Ethical Conduct of the Study 
This protocol is written in accordance with the principles established by the 18th World Medical 
Assembly General Assembly (Helsinki, 1964) and amendments and clarifications adopted by 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 65 of 84 
 
subsequent General Assemblies.  The investigator will make sure that the study described in this 
protocol is conducted in full conformance with those principles, the protocol, current FDA 
regulations, ICH Good Clinical Practices (GCP) guidelines, Good Laboratory Practices (GLP) 
guidelines, local ethical and regulatory requirements, including the Federal Food, Drug and 
Cosmetic Act, U.S. applicable Code of Federal Regulations (title 21), any EC requirements 
relative to clinical studies.  As required by the US FDA, the study drug may not be shipped to 
any participating investigator until the requisite study documentation has been submitted to the 
IND. 
Should a conflict arise, the investigator will follow whichever law or guideline affords the 
greater protection to the individual patient.  The investigator will also make sure he or she is 
thoroughly familiar with the appropriate administration and potential risks of administration of 
the study drug, as described in this protocol and the Investigator’s Brochure, prior to the 
initiation of the study. 
15.2. 
Ethics Committee/Institutional Review Board (EC/IRB) Review 
The EC/IRB must be a properly constituted board or committee operating in accordance with 21 
CFR Part 56, “Institutional Review Boards.”  This protocol, any protocol amendments, the 
associated informed consent forms, and the informed consent procedures must be submitted to 
the EC/IRB for review and approved before the enrollment of any patient into the trial. 
All types of patient recruitment or advertising information must be submitted to Tonix or its 
designee and to the EC/IRB for review and approval prior to implementation.  EC/IRB approval 
of any protocol amendments must be received before any of the changes outlined in the 
amendments are put into effect, except when the amendment has been enacted to eliminate a 
potential hazard to study patients.  In such cases, the chair of the EC/IRB should be notified 
immediately and the amendment forwarded to the EC/IRB for review and approval. 
15.3. 
Written Informed Consent 
It is the responsibility of the investigator to obtain signed written informed consent from each 
potential study patient prior to the conduct of any screening or other study procedures.  This 
written informed consent will be obtained after the methods, objectives, and potential risks of the 
study have been fully explained to the potential patient.  The investigator must explain to each 
patient that he or she is completely free to refuse to enter the study or to withdraw from it at any 
time.  NOTE:  Patients on serotoninergic medications (e.g., triptans) should be warned of a 
potential serious drug interaction and should be advised to contact their study site immediately if 
they experience any symptoms that might represent possible serotonin syndrome, including 
fever, confusion or agitation, hallucinations, sweating, high or low blood pressure, rapid heart 
rate, tremor, muscle rigidity or nausea, vomiting or diarrhea.  Patients on MAOIs should not be 
considered for the study, and MAOIs should not be initiated during the study due to the 
additional safety concerns posed by this class of medication when used in combination with 
other serotoninergic drugs (such as cyclobenzaprine). 
The patient should also be asked in the Informed Consent Form (ICF) for permission for the 
principal investigator or his designee to contact the patient’s other personal physicians, as 
appropriate, concerning participation in the study. 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 66 of 84 
 
The method of obtaining and documenting informed consent and the contents of the ICF will 
comply with International Conference on Harmonization (ICH) Good Clinical Practice (GCP) 
guidelines, the requirements of 21 CFR Part 50, “Protection of Human Patients,” the Health 
Insurance Portability and Accountability Act (HIPAA) regulations, and all other applicable 
regulatory requirements.  A properly executed written ICF shall be read, signed, and dated by 
each patient prior to entering the trial or prior to performing any study procedure.  The original 
signed and dated ICF will be kept on file at the study site.  Patients will be given a copy of the 
signed ICF and will be informed of any new developments during the course of the study that 
might influence their continued participation in the study. 
The investigator or a qualified designee will be available to answer each patient’s questions 
throughout the study, and all questions must be answered to the patient’s satisfaction.  If the 
protocol is amended and a revised ICF is introduced during the study, each patient’s further 
consent must be obtained.  The new version of the ICF must be approved by the EC, prior to 
subsequently obtaining each patient’s consent. 
Receipt of written informed consent will be documented in each patient’s or potential patient’s 
CRF.  The signed ICF must remain in each patient’s study file and must be available for 
verification by study monitors at all times. 
Separate written, signed informed consent must be obtained if the patient is to participate in the 
optional pharmacogenomic assessment. 
 
16. 
DATA HANDLING AND RECORDKEEPING 
16.1. 
Maintaining Privacy and Confidentiality 
In order to maintain patient privacy, all CRFs, study drug accountability records, and other 
documents, including communications between the study site and Tonix, will identify patients 
only by their initials or their assigned study identification numbers.  If required, the investigator 
will grant monitors and auditors from Tonix or its designee and/or regulatory authority’s access 
to patients’ original medical records for verification of the data gathered on the CRFs and to 
audit the data collection process.  Patients’ confidentiality will be maintained and will not be 
made publicly available. 
Special Provisions for Confidentiality:  A Certificate of Confidentiality (CoC) has been 
obtained from the FDA for the investigators to protect patients enrolled in the study.  Investigator 
can use the Certificate to avoid compelled "involuntary disclosure" (e.g., subpoenas, insurers, 
employers, or other third parties) of names and other identifying information about any 
individual who participates as a research patient (i.e., about whom the investigator maintains 
identifying information) during any time the Certificate is in effect. 
16.2. 
Maintaining Essential Clinical Documents 
Study site files for the retention of regulatory documents will be established at the beginning of 
the study, maintained for the duration of the study, and retained according to FDA and ICH/GCP 
guidelines and applicable regulatory requirements.  The records maintained must be adequate to 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 67 of 84 
 
fully document appropriate protection of study patients/patients, the validity of the study, the 
integrity of the data, and the manner in which the study was conducted. 
The investigator’s site file, copies of protocols, CRFs, originals of test result reports, drug 
disposition logs, correspondence, records of written informed consent, and other documents 
pertaining to the conduct of the study must be kept on file by the investigator and in readily 
accessible order for at least 2 years after the last approval of a marketing application, until at 
least 2 years have elapsed after formal discontinuation of the clinical development of the 
investigational product, or according to local regulatory requirements.  No study document may 
be destroyed without prior written consent from Tonix or its designee.  Should the investigator 
wish to withdraw from the responsibility of keeping the study records, custody must be 
transferred to a person willing to accept the responsibility.  Tonix must be notified in writing in 
advance if a custodial change is to occur.  It is important that the investigator remain ready to 
provide background information from the archived study records on request. 
The sponsor or designee will maintain adequate study records for at least 2 years after the last 
approval of a marketing application or for at least 2 years after clinical development of the study 
drug for the indication being studied has been discontinued.  After that period, the sponsor will 
be contacted to determine whether the study records will be forwarded to the sponsor, destroyed, 
or kept at the location of the designee or another facility for a longer period of time. 
16.3. 
Data Handling 
Unless otherwise specified, procedures, data collection and evaluation will be conducted as per 
the Standard Operating Procedures (SOPs) of the contract research organization (CRO).  The 
investigator will assume the responsibility of ensuring the completeness and accuracy of the 
clinical data.  All data will be verified for quality control and will also be patient to audits from 
Tonix or designee to ensure quality. 
All laboratory results will be analyzed by an accredited and licensed clinical laboratory facility.  
Clinical laboratory data will be transferred from the central laboratory to the clinical database 
maintained by the CRO using systems which are validated and Part 11-compliant. 
The responsible clinical study monitor(s) will check data at the monitoring visits to the clinical 
study site.  The investigator will ensure that the data collected are accurate, complete, and 
legible.  Any changes made to the clinical data will be documented with a full audit trail. 
Aspects of the clinical and statistical phases of the study, including all associated documentation 
may be reviewed by the Quality Assurance Unit of the contract research organization using a 
risk-assessment approach.  The final clinical and statistical report will be audited to ensure that, 
as far as can be reasonably established, the methods described and the results reported accurately 
reflect the raw data generated during the study. 
16.4. 
Case Report Forms (CRFs) 
The investigator is required to prepare and maintain adequate and accurate case histories 
designed to record all observations and other data pertinent to the study for each study patient.  
Data must be recorded on CRFs approved by Tonix or its designee.  Data (including AEs) will be 
recorded on raw data sheets and/or electronic or paper source documents. 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 68 of 84 
 
If selected data is collected via paper (patient questionnaires, etc.), the data must be entered into 
the eCRF and verified that it has been transcribed correctly. 
16.5. 
Screening Records 
A record generated by IWRS must be kept of all patients considered for the study who sign 
informed consent and who began any screening procedures.  The information should include the 
patient’ initials, unique patient identification numbers, whether they passed or failed screening, 
and, if they failed, the reason for screen failure. 
16.6. 
Clinical Laboratory Certification 
A central clinical laboratory will be used to analyze all samples in this study, with the exception 
of the urine pregnancy test and ad hoc urine drug screens.  The investigator must maintain, on 
file, written evidence that the central clinical laboratory to be used is certified under the Clinical 
Laboratory Improvement Act or equivalent certification (depending on local regulations).  
Further, the investigator will maintain a copy of the certification, the range of normal values, the 
effective dates for the ranges, and the units of measurement for all laboratory tests requested in 
the protocol.  If any of the laboratory measurements will be transformed and/or categorized in 
any way, a description of the procedures(s) used should be included.  The investigator is 
expected to receive these documents before the shipment of clinical supplies. 
16.7. 
Site Monitoring and Tonix’s Right to Review Records 
Monitoring and auditing procedures developed by Tonix and/or its designee will be implemented 
to ensure compliance with FDA and ICH GCP and GLP guidelines. 
Tonix’s designated representative (the monitor or auditor) will contact the investigator and 
conduct regular visits to the clinical site.  The monitor will be expected and allowed to verify the 
investigator’s qualifications, to inspect clinical site facilities, and to inspect study records, 
including proof of EC/IRB review, with the stipulation that patient confidentiality will be 
maintained in accordance with local and federal regulations, including HIPAA requirements.  
The monitor will also be responsible for confirming adherence to the study protocol, inspecting 
CRFs and source documents, and ensuring the integrity of the data.  CRFs will be checked for 
accuracy, completeness, and clarity and will be cross-checked for consistency with source 
documents, including laboratory test reports and other patient records.  Instances of missing or 
uninterpretable data will be resolved in coordination with the investigator. 
The monitor/auditor will also investigate any questions concerning adherence to regulatory 
requirements.  Any administrative concerns will be clarified and followed.  The monitor will 
maintain contact with the site through frequent direct communications with the study site by e-
mail, telephone, facsimile, and mail.  The investigator and all other site personnel agree to 
cooperate fully with the monitor and will work in good faith with the monitor to resolve any and 
all questions raised and difficulties detected by the monitor. 
16.8. 
Audits and Inspections 
The investigator understands that regulatory authorities, the EC/IRB, and/or Tonix or their 
designees have the right to access all CRFs, source documents, and other study documentation 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 69 of 84 
 
for on-site audit or inspection and will retain this right from the start of the study to at least 2 
years after the last approval of a marketing application or for at least 2 years after clinical 
development of the study drug for the indication being studied has been discontinued.  The 
investigator is required to guarantee access to these documents and to cooperate with and support 
such audits and inspections. 
17. 
CONFIDENTIALITY 
17.1. 
Protection of Patient Anonymity 
The investigator must make sure that each patient’s anonymity is maintained.  On CRFs or other 
documents submitted to Tonix or its agent, patient should not be identified by their names, but 
rather by their initials and the assigned study identification numbers.  The investigator should 
keep a separate record of the patient initials, randomization codes, patient names, address, and 
contact information.  Documents that contain the names associated with these initials and codes 
are not for submission to Tonix or its agents (e.g., written informed consent forms).  These 
records should be maintained by the investigator in strict confidence except to the extent 
necessary to allow auditing by regulatory authorities, Tonix, or its agents.  These records should 
be kept in compliance with HIPAA regulations. 
Special Provisions for Confidentiality:  In addition, Certificates of Confidentiality has been 
obtained from the FDA for the investigators to protect patients enroll in the study.  Investigators 
can use the Certificate to avoid compelled "involuntary disclosure" (e.g., subpoenas, insurers, 
employers, or other third parties) of names and other identifying information about any 
individual who participates as a research patient (i.e., about whom the investigator maintains 
identifying information) during any time the Certificate is in effect. 
17.2. 
Confidentiality of Study Information 
All information relevant to this study, whether supplied by Tonix or its agents to the investigator 
or collected by the investigator in support of this study, is privileged and confidential.  The 
investigator agrees to use this information to carry out the study and will not use it for other 
purposes without written consent from Tonix.  It is understood that the investigator is under 
obligation to provide Tonix with all data obtained during the study.  The information obtained 
from this study will be used by Tonix towards the clinical development of the indicated 
investigational drug and may be disclosed by Tonix to regulatory authorities, other investigators, 
corporate partners, or consultants as required. 
17.3. 
Publication of Data and Protection of Trade Secrets 
No presentations, abstracts (including meeting abstracts), or other publications based on the 
conduct or results of this study will be permitted without the express written permission of Tonix 
or its designated agent.  All such presentations or publications will proceed only as 
collaborations between Tonix and the investigators. 
If the investigator wishes to publish the results of this study, a copy of the proposed manuscript 
or abstract (including meeting abstracts) will be provided to Tonix or its designee for review, 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 70 of 84 
 
revision, and approval at least sixty (60) days before the expected date of submission for 
publication, unless otherwise arranged with Tonix in writing.  This will enable Tonix to protect 
its proprietary information and augment the publication with insights or information of which the 
investigator may not be aware. 
Patient names and other identifiers, such as photographs or audio or video recordings, may not 
be disclosed in any publication or public forum without prior written authorization from the 
patients involved or their legal guardians.  Tonix retains authority to delete any of its confidential 
information from such disclosures. 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 71 of 84 
 
18. 
LIST OF REFERENCES 
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th 
Edition: DSM-5. May 2013. 
Bahk WM, Pae CU, Tsoh J, Chae JH, et al. Effects of mirtazapine in patients with post-traumatic 
stress disorder in Korea: A pilot study.  Hum Psychopharmacol 2002; 17(7):341-244. 
Bajor LA, Ticlea AN, Osser DN.  The Psychopharmacology Algorithm Project at the Harvard 
South Shore Program: An update on posttraumatic stress disorder.  Harv Rev Psychiatry 2011 
Sep-Oct; 19 (5):240-258. 
Barnes CD, Fung SJ, Gintautas J.  Brainstem noradrenergic system depression by 
cyclobenzaprine.  Neuropharmacology 1980 Feb; 19 (2):221-224. 
Berridge CW, Schmeichel BE, Espãna RA.  Noradrenergic modulation of wakefulness/arousal. 
Sleep Med Rev 2012; 16(2):187-97. 
Betts KS, Williams GM, Najman JM, Alati R.  The role of sleep disturbance in the relationship 
between post-traumatic stress disorder and suicidal ideation.  J Anxiety Disord 2013; 27(7):735-
41. 
Breslau N, Roth T, Burduvali E, Kapke A, Schultz L, Roehrs T. Sleep in lifetime posttraumatic 
stress disorder: a community-based polysomnographic study. Arch Gen Psychiatry 2004 May; 
61(5):508-516. Erratum in: Arch Gen Psychiatry 2005 Feb; 62(2):172. 
Capaldi VF 2nd, Guerrero ML, Killgore WD. Sleep disruptions among returning combat 
veterans from Iraq and Afghanistan. Mil Med 2011 Aug; 176 (8):879-888. 
Connor KM, Davidson JR, Weisler RH, Ahearn E.  A pilot study of mirtazapine in post-
traumatic stress disorder.  Int Clin Psychopharmacol 1999 Jan; 14(1):29-31. 
Cui L, Hung HM, Wang SJ. Modification of sample size in group sequential clinical trials. 
Biometrics. 1999;55(3):853-7 
Datta S, Guangmu Li, Sanford A. Activation of phasic pontine-wave generator in the rat: a 
mechanism for expression of plasticity-related genes and proteins in the dorsal hippocampus and 
amygdala. Eur J Neurosci. 2008 April ; 27(7): 1876–1892. 
Datta S, O'Malley MW. Fear extinction memory consolidation requires potentiation of pontine-
wave activity during REM sleep. J Neurosci. 2013;33:4561-4569. 
Davidson JR, Weisler RH, Butterfield MI, Casat CD, et al. Mirtazapine vs. placebo in 
posttraumatic stress disorder: A pilot trial.  Biol Psychiatry 2003 Jan 15; 53(2):188-191. 
Davidson JR, Weisler RH, Malik ML, Connor KM.  Treatment of posttraumatic stress disorder 
with nefazodone.  Int Clin Psychopharmacol 1998 May; 13(3):111-113. 
Davis LL, Jewell ME, Ambrose S, Farley J, et al. A placebo-controlled study of nefazodone for 
the treatment of chronic posttraumatic stress disorder: a preliminary study. J Clin 
Psychopharmacol. 2004 Jun; 24(3):291-7. 
Germain A. Sleep disturbances as the hallmark of PTSD: Where are we now? Am J Psychiatry 
2013; 170:372-382. 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 72 of 84 
 
Halász P1, Terzano M, Parrino L, Bódizs R. The nature of arousal in sleep. J Sleep Res 2004; 
13(1):1-23. 
Hertzberg MA, Feldman ME, Beckham JC, Davidson JR.  Trial of trazodone for posttraumatic 
stress disorder using a multiple baseline group design.  J Clin Psychopharmacol 1996 Aug; 
16(4):294-298. 
Hertzberg MA, Feldman ME, Beckham JC, Moore SD, Davidson JR.  Open trial of nefazodone 
for combat-related posttraumatic stress disorder.  J Clin Psychiatry 1998 Sep; 59(9):460-464. 
Hidalgo R, Hertzberg MA, Mellman T, Petty F, et al. Nefazodone in post-traumatic stress 
disorder: Results from six open-label trials.  Int Clin Psychopharmacol 1999 Mar; 14(2):61-68. 
Hoge, C. W., McGurk, D., Thomas, J.L., Cox, A.L., Engel, C.C. & Castro, C.A. Mild traumatic 
brain injury in US soldiers returning from Iraq. New England Journal of Medicine 2008; 358, 
453–463. 
Honda M, Nishida T, Ono H.  Tricyclic analogs cyclobenzaprine, amitriptyline and 
cyproheptadine inhibit the spinal reflex transmission through 5-HT(2) receptors.  Eur J 
Pharmacol 2003 Jan 1; 458(1-2):91-99. 
Huang ZL, Mochizuki T, Qu WM, Hong ZY, Watanabe T, Urade Y, Hayaishi O. Altered sleep-
wake characteristics and lack of arousal response to H3 receptor antagonist in histamine H1 
receptor knockout mice. Proceedings of the National Academy of Sciences of the United States 
of America. 2006;103:4687-4692. 
Karashima A, Katayama N, Nakao M. Enhancement of Synchronization Between Hippocampal 
and Amygdala Theta Waves Associated With Pontine Wave Density. J Neurophysiol 103: 2318–
2325, 2010. 
Keller A, McGarvey EL, Clayton AH. Reliability and construct validity of the changes in sexual 
functioning questionnaire Short form (CSFQ-14). J of Sex and Marital Ther. 2006; 32:43-52. 
Kelly UA, Skelton K, Patel M, Bradley B. More than military sexual trauma: interpersonal 
violence, PTSD, and mental health in women veterans. Res Nurs Health. 2011;34:457-467. 
Kim W, Pae CU, Chae JH, Jun TY, Bahk WM.  The effectiveness of mirtazapine in the treatment 
of post-traumatic stress disorder: a 24-week continuation therapy.  Psychiatry Clin Neurosci 
2005 Dec; 59(6):743-747. 
Kobayashi H, Hasegawa Y, Ono H.  Cyclobenzaprine, a centrally acting muscle relaxant, acts on 
descending serotonergic systems.  Eur J Pharmacol 1996 Sep 5; 311(1):29-35.  
Kobayashi I, Boarts JM, Delahanty DL. Polysomnographically measured sleep abnormalities in 
PTSD: A meta-analytic review. Psychophysiology 2007; 44(4):660-669. 
Koren D, Arnon I, Lavie P, Klein E.  Sleep complaints as early predictors of posttraumatic stress 
disorder: A 1-year prospective study of injured survivors of motor vehicle accidents.  Am J 
Psychiatry 2002 May; 159(5):855-857. 
Krakow B, Artar A, Warner TD, Melendrez D, et al.  Sleep disorder, depression, and suicidality 
in female sexual assault survivors.  Crisis 2000; 21(4):163-170. 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 73 of 84 
 
Krakow B, Melendrez D, Johnston L, Warner TD, et al.  Sleep-disordered breathing, psychiatric 
distress, and quality of life impairment in sexual assault survivors.  J Nerv Ment Dis 2002 Jul; 
190(7):442-452. 
Krakow B, Melendrez D, Pedersen B, Johnston L, et al.  Complex insomnia: Insomnia and sleep-
disordered breathing in a consecutive series of crime victims with nightmares and PTSD.  Biol 
Psychiatry 2001; 49(11):948-953. 
Krystal AD, Zhang W, Davidson JR, Connor KM.  The sleep effects of tiagabine on the first 
night of treatment predict post-traumatic stress disorder response at three weeks.  J 
Psychopharmacol 2013; Nov 28 [epub ahead of print]. 
Lewis JD.  Mirtazapine for PTSD nightmares.  Am J Psychiatry 2002 Nov; 159(11):1948-1949. 
Llorca PM, Spadone C, Sol O, Danniau A, Bougerol T, Corruble E, Faruch M, Macher JP, 
Sermet E, Servant D. Efficacy and safety of hydroxyzine in the treatment of generalized anxiety 
disorder: a 3-month double-blind study. J Clin Psychiatry. 2002;63:1020-1027. 
Maren S, Phan KL, Liberzon I. The contextual brain: implications for fear conditioning, 
extinction and psychopathology. Nat Rev Neurosci. 2013;14:417-428. 
McLay RN, Klam WP, Volkert SL.  Insomnia is the most commonly reported symptom and 
predicts other symptoms of post-traumatic stress disorder in U.S. service members returning 
from military deployments.  Mil Med 2010; 175(10):759-762. 
Mellman TA, Bustamante V, Fins AI, Pigeon WR, Nolan B.  REM sleep and the early 
development of posttraumatic stress disorder.  Am J Psychiatry 2002 Oct; 159(10):1696-1701. 
Mellman TA, David D, Kulick-Bell R, Hebding J, Nolan B. Sleep disturbance and its 
relationship to psychiatric morbidity after Hurricane Andrew. Am J Psychiatry. 1995;152:1659-
1663. 
Moldofsky H, Harris HW, Archambault WT, Kwong T, Lederman S.  Effects of bedtime very 
low dose cyclobenzaprine on symptoms and sleep physiology in patients with fibromyalgia 
syndrome: A double-blind randomized placebo-controlled study.  J Rheumatol 2011; 38(10):1-
11. 
Montgomery SA and Asberg, M. A new depression scale designed to be sensitive to change. The 
British Journal of Psychiatry 1979; 134: 382-389. 
Monti JM. Serotonin control of sleep-wake behavior. Sleep Med Rev. 2011;15:269-281. 
Neylan TC, Lenocil M, Maglione ML, Rosenlicht NZ, et al. Delta Sleep Response to 
Metyrapone in Post-Traumatic Stress Disorder. Neuropsychopharmacology 2003; 28: 1666–
1676. 
Neylan TC, Marmar CR, Metzler TJ, Weiss DS, Zatzick DF, Delucchi KL, Wu RM, Schoenfeld 
FB. Sleep disturbances in the Vietnam generation: findings from a nationally representative 
sample of male Vietnam veterans. Am J Psychiatry. 1998;155:929-933. 
Oquendo MA, Friend JM, Halberstam B, Brodsky BS, et al. Association of comorbid 
posttraumatic stress disorder and major depression with greater risk for suicidal behavior. Am J 
Psychiatry 2003; 160(3):580-2. 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 74 of 84 
 
Pace-Schott EF, Germain A, Milad MR. Sleep and REM sleep disturbance in the 
pathophysiology of PTSD: the role of extinction memory. Biol Mood Anxiety Disord. 2015;5:3. 
Pace-Schott EF, Milad MR, Orr SP, Rauch SL, Stickgold R, Pitman RK. Sleep promotes 
generalization of extinction of conditioned fear. Sleep. 2009;32:19-26. 
Pietrzak RH, Morgan CA, 3rd, Southwick SM. Sleep quality in treatment-seeking veterans of 
Operations Enduring Freedom and Iraqi Freedom: the role of cognitive coping strategies and unit 
cohesion. J Psychosom Res. 2010;69:441-448. 
Raskind MA, Peskind ER, Hoff DJ, Hart KL, et al.  A parallel group placebo controlled study of 
prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic 
stress disorder.  Biol Psychiatry 2007 Apr 15; 61(8):928-934. 
Raskind MA, Peskind ER, Kanter ED, Petrie EC, et al. Reduction of nightmares and other PTSD 
symptoms in combat veterans by prazosin: A placebo-controlled study.  Am J Psychiatry 2003 
Feb; 160(2):371-373. 
Raskind MA, et al. Trial of prazosin for Post-Traumatic Stress Disorder in Military Veterans. 
NEJM 2018;378:507-517. 
Resick A et al and the STRONG STAR Consortium.  Effect of Group vs Individual Cognitive 
Processing Therapy in Active-Duty Military Seeking Treatment for Posttraumatic Stress 
Disorder.  JAMA Psychiatry 2017; 74(1):28-36. 
Saladin ME, Brady KT, Dansky BS, Kilpatrick DG.  Understanding comorbidity between PTSD 
and substance use disorders: two preliminary investigations.  Addict Behav 1995 Sep-Oct; 
20(5):643-655. 
Sareen J, Houlahan T, Cox BJ, Asmundson GJ. Anxiety disorders associated with suicidal 
ideation and suicide attempts in the National Comorbidity Survey. J Nerv Ment Dis 2005; 
193(7):450-4. 
Serafim KR, Gianlorenco AC, Daher FP, Mattioli R. H1-histamine receptors in the amygdala are 
involved in emotional memory but do not mediate anxiety-related behaviors in mice submitted to 
EPM testing. Brain research bulletin. 2012;89:1-7. 
Serafim KR, Kishi MS, Canto-de-Souza A, Mattioli R. H(1) but not H(2) histamine antagonist 
receptors mediate anxiety-related behaviors and emotional memory deficit in mice subjected to 
elevated plus-maze testing. Brazilian journal of medical and biological research = Revista 
brasileira de pesquisas medicas e biologicas / Sociedade Brasileira de Biofisica  [et al]. 
2013;46:440-446. 
Sheehan DV, Lecrubier Y, Sheehan K, AmorinP, et al.  The Mini-International Neuropsychiatric 
Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric 
interview for DSM-IV and ICD-10.  J Clin Psychiatry 1998; 59(Suppl 20):22-33. 
Sheehan KH & Sheehan DV.  Assessing treatment effects in clinical trials with the Discan metric 
of the Sheehan Disability Scale. Int Clin Psychopharmacol 2008:23:70-83. 
Siwek DF, Knapp CM, Kaur G, Datta S. Dorsal subcoeruleus nucleus (SubCD) involvement in 
context-associated fear memory consolidation. Exp Brain Res. 2014;232:1535-1545. 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 75 of 84 
 
Spoormaker VI, Montgomery P.  Disturbed sleep in post-traumatic stress disorder: secondary 
symptom or core feature?  Sleep Med Rev 2008 Jun; 12(3):169-184. 
Stanley B and Brown GK.  Safety planning intervention: A brief intervention to mitigate suicide 
risk.  Cognitive and Behavioral Practice 2012; 19:256-264. 
Steine IM, Harvey AG, Krystal JH, Milde AM, Gronli J, Bjorvatn B, Nordhus IH, Eid J, Pallesen 
S. Sleep disturbances in sexual abuse victims: a systematic review. Sleep Med Rev. 2012;16:15-
25. 
Taylor FB, Lowe K, Thompson C, McFall MM, et al. Daytime prazosin reduces psychological 
distress to trauma specific cues in civilian trauma posttraumatic stress disorder.  Biol Psychiatry 
2006 Apr 1; 59(7):577-81.  
Taylor FB, Martin P, Thompson C, Williams J, et al. Prazosin effects on objective sleep 
measures and clinical symptoms in civilian trauma posttraumatic stress disorder: A placebo-
controlled study.  Biol Psychiatry 2008 Mar 15; 63(6):629-632. 
Warner MD, Dorn MR, Peabody CA.  Survey on the usefulness of trazodone in patients with 
PTSD with insomnia or nightmares.  Pharmacopsychiatry 2001 Jul; 34(4):128-131. 
Weathers FW, Blake DD, Schnurr PP, Kaloupek DG, et al.  The Life Events Checklist for DSM-
5 (LEC-5). 2013:  Instrument available from the National Center for PTSD at www.ptsd.va.gov. 
Weathers FW, Blake DD, Schnurr PP, Kaloupek DG, Marx, et al. The Clinician-Administered 
PTSD Scale for DSM-5 (CAPS-5). 2013: Instrument available from the National Center for 
PTSD at www.ptsd.va.gov. 
Woodward SH, Arsenault NJ, Murray C, Bliwise DL. Laboratory sleep correlates of nightmare 
complaint in PTSD inpatients. Biol Psychiatry 2000; 48(11):1081-7. 
Woodward SH, Leskin GA, Sheikh JI. Movement during sleep: associations with posttraumatic 
stress disorder, nightmares, and comorbid panic disorder. Sleep 2002; 25(6):681-8. 
Wright KM, Britt TW, Bliese PD, Adler AB, Picchioni D, Moore D.  Insomnia as predictor 
versus outcome of PTSD and depression among Iraq combat veterans.  J Clin Psychol 2011 Dec; 
67(12):1240-58. 
Yehuda R, LeDoux J. Response variation following trauma: a translational neuroscience 
approach to understanding PTSD. Neuron. 2007;56:19-32. 
Yoo SS, Gujar N, Hu P, Jolesz FA, Walker MP. The human emotional brain without sleep--a 
prefrontal amygdala disconnect. Curr Biol. 2007;17:R877-878. 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 76 of 84 
 
19. 
APPENDICES 
APPENDIX 1. STUDY DESIGN AND SCHEDULE OF ASSESSMENTS 
Period 
Screening 
Baseline 
Double-Blind Treatment Period 
Visit 
1 
2 
3a 
4 
5 
6 
Study Week 
-3 to -1  
0 
2 
4 
8 
12 
Study Day 
-21 to -7 
1 
14 ± 3  
28± 5 
56 ± 5 
84 -5/+7 
Informed Consent 
X 
 
 
 
 
 
Inclusion/Exclusion Criteria  
X 
X 
 
 
 
 
Randomization  
 
X 
 
 
 
 
Psychiatric History (M.I.N.I. 7.0.2)  
X 
 
 
 
 
 
MSI-BPD 
X 
 
 
 
 
 
Demographics and Medical History  
X 
Xb 
 
 
 
 
Prior and Concomitant Medications  
X 
X 
X 
X 
X 
X 
Vital Signs, heightc, weight and BMI  
X 
X 
 
X 
X 
X 
Physical Examination  
X 
 
 
 
 
 
Inspection of oral cavity 
X 
Xd 
 
 
 
X 
12-Lead Electrocardiogram  
X 
 
 
 
 
 
Pregnancy Teste 
Xf 
X 
 
X 
X 
Xf 
Urine Drug Screen  
X 
Xg 
 
 
 
 
Clinical Laboratory Assessmentsh 
X 
 
 
 
 
X 
HIV, and TSH  
X 
 
 
 
 
 
MADRS 
X 
X 
 
X 
X 
X 
LEC-5  
X 
 
 
 
 
 
CA-AF 
X 
 
 
 
 
 
CAPS-5  
Xi 
Xj, k 
 
Xk 
Xk 
Xk 
C-SSRS 
Xl 
Xm 
Xm 
Xm 
Xm 
Xm 
CGI-I 
 
 
 
X 
X 
X 
CGI-S 
 
X 
 
X 
X 
X 
PGIC 
 
 
 
X 
X 
X 
PROMIS-sleep (short form) 
 
X 
 
X 
X 
X 
CSFQ-14 
 
X 
 
 
 
X 
SDS 
 
X 
 
X 
X 
X 
Pharmacogenomic blood draw 
(optional)o 
 
* 
 
* 
* 
* 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 77 of 84 
 
Period 
Screening 
Baseline 
Double-Blind Treatment Period 
Visit 
1 
2 
3a 
4 
5 
6 
Study Week 
-3 to -1  
0 
2 
4 
8 
12 
Study Day 
-21 to -7 
1 
14 ± 3  
28± 5 
56 ± 5 
84 -5/+7 
Adverse Events 
 
X 
X 
X 
X 
X 
Telephone Visita 
 
 
X 
 
 
 
Dispense Study Drugn 
 
X 
 
X 
X 
 
Collect/ Count Study Drug Returned 
 
 
 
X 
X 
X 
Abbreviations:  BMI = Body Mass Index; CA-AF = Criterion A – Assessment Form; CAPS-5 = Clinician 
Administered PTSD Scale (for DSM-5); CGI-I = Clinical Global Impression – Improvement scale; CGI-S = Clinical 
Global Impression – Severity scale; CSFQ-14=Changes in Sexual Functioning Questionnaire Short-Form; C-SSRS 
= Columbia-Suicide Severity Rating Scales; HIV = Human immunodeficiency virus; LEC-5 = Life Events Checklist 
for DSM-5; MADRS = Montgomery-Åsberg Depression Rating Scale; M.I.N.I = Mini International 
Neuropsychiatric Interview; MSI-BPD = McLean Screening Instrument for Borderline Personality Disorder; PGIC 
= Patient Global Impression of Change; PROMIS = Patient Reported Outcomes Measurement Information System; 
SDS = Sheehan Disability Scale; TSH=Thyroid Stimulating Hormone;  
a Week 2 visit will be performed via telephone.  The patient will be asked about Adverse Events 
(including oral AEs), any change in medication, and study drug dosing and compliance and conduct the 
C-SSRS. 
b Only updates from screening 
c Height to be measured at Visit 1 only 
d In addition to the regularly scheduled examination, a visual examination of the oral cavity should be 
done at any visit in which an oral adverse event has been reported. 
e Women of child-bearing potential only 
f Serum pregnancy test required at Visit 1 only; all other pregnancy tests via urine dipstick performed in 
the clinic. Serum pregnancy test at Visit 6/Early Termination may be done at Investigator’s discretion. 
g Urine dipstick to confirm eligibility if Visit 1 results were positive for excluded medication such as 
opiates, amphetamines etc. requiring washout. Patients with positive results for Benzodiazepines at 
Screening will come in to the clinic for repeat centralized Urine Drug Screen following a week of drug 
free interval. 
h  Chemistry and hematology 
i  Visit 1 CAPS-5 will utilize the “Diagnostic Version” (past month recall). Patients must meet criteria for 
diagnosis of PTSD and have a total score ≥29 
j  Total CAPS-5 score must be ≥33 (“Symptom Severity Version” using 1-week recall) 
k CAPS-5 “Symptom Severity Version” using 1-week recall 
l C-SSRS (“Baseline/Screening” Version) 
m C-SSRS (“Since Last Visit” Version) 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 78 of 84 
 
n Four-week supply of study medication will be dispensed at each dispensing visit. Must access IWR 
system in order to obtain correct bottle number to dispense 
*/oThe blood draw for the pharmacogenomic assessment can be obtained at any study visit post-
Screening (including an early termination visit).  It should only be obtained one time during the study.  
Separate written, signed informed consent is required if the patient is to participate in the optional 
pharmacogenomic assessment.  
 
 
 
 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 79 of 84 
 
APPENDIX 2. LIST OF CYP3A INHIBITORS 
 
Taken from Table 3, FDA Draft Guidance for Industry:  Drug Interaction Studies—Study 
Design, Data Analysis, Implications for Dosing, and Labeling Recommendations; Feb 2012; 
updated Sept. 26, 2016).  Excluded strong CYP3A4 inhibitors are listed in the far left column of 
the table.  
 
 
Strong Inhibitors  
 
≥ 5-fold increase in AUC   
Or, > 80% decrease in CL  
Moderate Inhibitors   
 
≥ 2 but < 5-fold increase in AUC   
Or 50-80% decrease in CL  
Weak Inhibitors  
 
≥ 1.25 but < 2-fold increase in 
AUC   
Or, 20-50% decrease in CL  
CYP3A4  
boceprevir  
clarithromycin   
cobicistat  
conivaptan  
danoprevir  
elvitegravir  
grapefruit juice   
indinavir   
itraconazole  
ketoconazole   
lopinavir    
mibefradil  
nefazodone  
nelfinavir  
paritaprevir  
posaconazole  
ritonavir   
saquinavir   
telaprevir  
telithromycin  
tipranavir  
troleandomycin  
voriconazole  
 
amprenavir  
aprepitant  
atazanavir  
cimetidine  
ciprofloxacin  
clotrimazole  
crizotinib  
cyclosporine  
darunavir/ritonavir  
diltiazem  
dronedarone  
erythromycin  
fluconazole  
fluvoxamine  
fosamprenavir  
imatinib  
tofisopam  
verapamil  
alprazolam  
amiodarone  
amlodipine  
atorvastatin  
bicalutamide  
chlorzoxazone  
cilostazol  
fosaprepitant  
fluoxetine  
gingko  
goldenseal   
isoniazid  
istradefylline  
ivacaftor  
lapatinib  
lomitapide  
nilotinib  
oral contraceptives  
pazopanib  
ranitidine  
ranolazine  
tacrolimus  
tipranavir/ritonavir  
ticagrelor  
zileuton  
Source:  Table 3-2, 
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm  

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 80 of 84 
 
APPENDIX 3. AMRIX® PACKAGE INSERT (DATED APRIL 2019) 
 
 
 
 
 
 
 
 
 
 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 81 of 84 
 
 
 
 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 82 of 84 
 
 
 
 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 83 of 84 
 
 
 

Protocol No. TNX-CY-P302  
 
CONFIDENTIAL 
 
 
 
Version 1.3, December 23, 2019 
 
Page 84 of 84